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Summary 
Cachexia is a prognostically important development in patients with heart failure. The 
most commonly used definition of cardiac cachexia is loss of a percentage of body 
weight over time. Muscle wasting has been assumed to be the major contributor to 
this weight loss, and cytokine activation is postulated to be central to the 
pathogenesis. We hypothesised that elevated circulating cytokines in cachectic heart 
failure patients would be associated with muscle inflammation, injury and impaired 
ability to repair. 
 
The aim of this doctoral work was to characterise the nature of cachexia in patients 
with heart failure (HF) and stable coronary artery disease (CAD), to quantify the loss 
of muscle mass, and test the hypothesis that muscle wasting is mediated by the 
activation of tissue cytokines and cell cycle inhibitors. 
 
We studied five subject groups. Three were groups of patients with stable coronary 
artery disease: 1) HF-cachexia - patients with HF, reduced left ventricular systolic 
function and cachexia, n=10; 2) HF-no cachexia - those with HF, reduced systolic 
function but no cachexia, n=20; and 3) CAD - those with CAD, no symptoms of HF 
and preserved systolic function, n=10. The other subject groups were: 4) IDCM ￿ 
patients with idiopathic dilated cardiomyopathy, n=7; and 5) HC ￿ healthy controls, 
n=9.  
 
Subjects were characterised by New York Heart Association (NYHA) classification, 
left ventricular ejection fraction (LVEF), peak oxygen consumption (VO2), weight  9
history and body composition analysis. Circulating levels of tumour necrosis factor-α 
(TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), leptin, adiponectin, and B-
type natriuretic peptide (BNP) were measured. Skeletal muscle biopsies were 
analysed for the expression of messenger ribonucleic acid (mRNA) for TNF-α, IL-6, 
interleukin-1β (IL-1β), interleukin-18 (IL-18) and the cell cycle inhibitors (cyclin 
dependent kinase (CDK) inhibitors) p21, p27 and p57. 
 
We found that the HF-cachexia group had significantly lower body mass index (BMI) 
and percentage body fat than all the other subject groups. In contrast, there was no 
significant reduction in fat free mass index (FFMI). In addition, the HF-cachexia 
group had higher rates of fat oxidation than all other groups. 
 
While the HF-cachexia group had elevated circulating levels of TNF-α and IL-6, 
there was no increased expression of cytokines or CDK inhibitors in the skeletal 
muscle. 
 
Circulating adiponectin and BNP levels were elevated in the HF-cachexia group. 
There was a positive association between adiponectin and BNP, and a negative 
relationship of each with BMI and percentage body fat. In addition, adiponectin 
positively correlated with rate of fat oxidation and TNF-α concentration. 
 
A possible causal relationship between adiponectin and increased rate of fat oxidation 
was further investigated in an additional study of young healthy male subjects 
performing an exercise program specifically designed to maximise fat metabolism  10
(n=11). Despite inducing significantly increased rates of fat oxidation and adiponectin 
concentrations no relationship was observed between them.    
 
In conclusion, cachexia in patients with heart failure and stable coronary artery 
disease predominantly involves the loss of adipose tissue, with no evidence of muscle 
wasting or inflammation. The presence of increased circulating levels of adiponectin 
and BNP, their association with each other, and the relationship of each with body 
composition, energy metabolism and TNF-α suggests these peptides may play an 
important role in the pathogenesis of cardiac cachexia.  11
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CHAPTER 1 
 
GENERAL INTRODUCTION  19
Introduction 
Cachexia is the wasting process associated with malignancy and chronic disease, 
involving the loss of skeletal muscle, adipose tissue and bone. Although cachexia has 
been identified as a prognostically important development in heart failure, its 
definition, aetiology and pathophysiology remain the subject of debate (Anker et al, 
1997; Von Haehling et al, 2007). 
 
Muscle wasting has commonly been assumed to be the major contributor to weight 
loss in cardiac cachexia. While cytokine activation is one of the most frequently 
postulated causes of cachexia in heart failure, ageing, muscular dystrophy, and other 
chronic diseases are known to be associated with activation of cell cycle inhibitors, 
impairing proliferation of muscle progenitor cells and muscle repair. (Levine et al, 
1990; McMurray et al, 1991; Dutka et al, 1993; Anker et al, 1997; Welle et al, 2004; 
Endesfelder et al, 2000; Dasarathy et al, 2004; Fulds, 2005). 
 
More recently, it has been suggested that the loss of body fat is of prognostic 
importance in heart failure, stimulating interest in adipose tissue derived cytokines 
and hormones, and the regulation of energy metabolism (Lavie et al, 2003).  20
Heart Failure 
Definition of heart failure 
Heart failure is a common, costly, disabling and deadly disease with increasing 
prevalence. Heart Failure has been defined by both the European Society of 
Cardiology (ESC) Task Force and the American College of Cardiology/American 
Heart Association (ACC/AHA) (Swedberg et al, 2005; Hunt et al, 2005). The ESC 
guidelines define heart failure as ￿a syndrome where the patients should have the 
following features; symptoms of heart failure, typically breathlessness or fatigue, 
either at rest or during exertion, or ankle swelling, and objective evidence of cardiac 
dysfunction at rest.￿ Similarly, the ACC/AHA guidelines define heart failure as a 
￿clinical syndrome that is characterised by specific symptoms (dyspnoea and fatigue) 
and signs (fluid retention)￿ and states that ￿there is no diagnostic test for heart failure, 
because it is largely a clinical diagnosis that is based on a careful history and physical 
examination.￿ It continues ￿Heart failure is a complex clinical syndrome that can 
result from any structural or functional cardiac disorder that impairs the ability of the 
ventricle to fill with or eject blood￿. 
 
Epidemiology of heart failure 
The combination of improved survival post myocardial infarction and the ageing 
population has lead to an increase in the prevalence of heart failure. In Scotland in the 
year 2000 the prevalence of heart failure was 7.1 in 1000, increasing with age to 90.1 
in 1000 in patients >85 years (Murphy et al, 2004). By 1999, in the USA, 
hospitalisations with heart failure had increased to over 1 million per annum 
(Koelling et al, 2004).  21
The cost of managing heart failure in the early 1990s was estimated to be 1￿2% of 
total health care expenditure in industrialised countries, with this likely to be a 
considerable underestimate of current costs with increased prevalence and 
hospitalisation rates through the 1990s (McMurray et al, 1998).  
 
The Framingham study reported a mortality rate of approximately 60% within five 
years of a diagnosis of heart failure (Ho et al, 1993). In Scotland in 1991 patients 
admitted to hospital with a first presentation of heart failure had a five-year survival 
of only 25%. With the exception of lung cancer, survival with heart failure was worse 
than with all the other most common cancers and with myocardial infarction (Stewart 
et al, 2001). 
 
Aetiology of heart failure 
In western countries coronary artery disease followed by hypertension and dilated 
cardiomyopathy are the most common causes of heart failure. In 1965 the 
Framingham study found hypertension to be the most common cause, being the 
primary cause in 30% of men and 20% of women. During long-term follow up the 
prevalence of coronary artery disease increased in the population and became the 
primary cause of heart failure in 70% of cases in the 1970s. At the same time the 
relative contribution of hypertension and valvular heart disease declined (Kannel et 
al, 1994). This is also reflected in more recent large clinical trials and registry 
populations (McMurray et al, 2000). A Glasgow study of left ventricular systolic 
dysfunction found that, in patients who also had symptoms of heart failure, 95% had  22
evidence of coronary artery disease, 80% hypertension and 25% valvular heart 
disease (McDonagh et al, 1997).  23
Cachexia in Heart Failure 
A wasting process similar to that observed in malignancy and other chronic diseases 
also develops in heart failure. Heart failure patients who develop cachexia have the 
greatest symptomatic limitation and poorest prognosis. In 1997 Anker et al found 
cachexia to be a strong independent predictor of reduced survival, with an 18 months 
mortality of 50% in heart failure patients with cachexia compared to 17% in those 
without cachexia (figure 1.1) (Anker et al, 1997). This relatively small, single centre 
study has become the cornerstone of cardiac cachexia research over the last 10 years. 
 
Figure 1.1. Kaplan-Meier survival and cumulative hazard curves for 18-month 
survival of 171 patients with CHF (Anker et al, 1997). Legend reproduced as 
originally published but incorrect. Should read: ○ Non-cachectic and peak VO2 ≥14 mL.Kg
-
1.min
-1; ● Cachectic and peak VO2 ≥14 mL.Kg
-1.min
-1; □ Non-cachectic and peak VO2 <14 
mL.Kg
-1.min
-1; ■ Cachectic and peak VO2 <14 mL.Kg
-1.min
-1. 
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The exact cause (or causes) of cardiac cachexia is unknown. Pro-inflammatory 
cytokines, increased neurohumoral activity, undernutrition, anabolic-catabolic 
hormone imbalance and immune activation have all been implicated (Levine et al, 
1990; Anker et al, 1997; Anker et al, 1999). 
 
Definition of cachexia 
Early studies of cardiac cachexia specifically assessed percentage body fat and 
defined cachexia as <27% body fat in males and <29% in females (Murdoch et al, 
1999). In chronic obstructive pulmonary disease (COPD) a definition of a body mass 
index (BMI) <23 kg/m
2 and a fat-free mass index (FFMI) <15 kg/m
2 in females and 
<16 kg/m
2 in males has been adopted, with the emphasis on loss of skeletal muscle 
(fat free mass) (American Thoracic Society and European Respiratory Society, 1999). 
The most commonly used operational definition of cachexia in recent heart failure 
studies derives from the study by Anker et al, as an unintentional weight loss of 
≥ 7.5% body weight over a period of at least 6 months (Anker et al, 1997). While 
arbitrary, and providing no information on the relative change in body composition, 
this definition is easily applicable in the clinical environment and has been widely 
adopted. More recent post-hoc analysis of data regarding weight change during the 
Studies of Left Ventricular Dysfunction (SOLVD) trial suggested that >6% weight 
loss is a more powerful predictor of outcome (Anker et al, 2003). 
 
Epidemiology of cardiac cachexia 
There is limited knowledge of the incidence and prevalence of cachexia in heart 
failure. In the SOLVD (Studies of Left Ventricular Dysfunction) treatment study,  25
investigating the effect of enalapril in heart failure with left ventricular systolic 
dysfunction, 28% of patients had ≥7.5% weight loss during a mean follow-up of 35 
months. Between 24 and 36 months follow-up the proportion of patients with ≥7.5% 
weight loss increased from 10% to 14% in the treatment group and 13% to 15% in the 
placebo group (Anker et al, 2003). Castillo-Martinez et al reported a 6 months 
incidence of cachexia (defined as weight loss >6% in 6 months) of 19% in a small, 
single centre study (Castillo-Martinez et al, 2005). 
 
Systemic inflammation in cardiac cachexia 
Heart failure is associated with elevated circulating levels of inflammatory mediators. 
Increased levels of the inflammatory cytokine tumour necrosis factor alpha (TNF-α) 
correlate with disease severity and may contribute to disease progression (Levine et 
al, 1990; Torre-Amione et al, 1996; Torre-Amione et al, 2000). Contrary to this 
hypothesis, anti-cytokine therapy in the form of etanercept, a TNF-α antagonist, or 
infliximab, an antibody to TNF-α, had no effect on clinical status, death or 
hospitalisation in patients with heart failure at 6 months follow-up (Chung et al, 2003; 
Mann et al, 2004). 
 
The presence of a more pronounced inflammatory response, and more specifically 
higher circulating levels of TNF-α, has been observed in patients with cardiac 
cachexia. This has lead to the suggestion that the inflammatory cytokines may play a 
role in the wasting process. (Levine et al, 1990; McMurray et al, 1991; Dutka et al, 
1993; Anker et al, 1997).  
  26
Tissue inflammation in cardiac cachexia 
It is speculated that the presence of marked systemic inflammation may be associated 
with muscle inflammation and tissue cytokine activation. The only previous study 
quantifying muscle cytokine activation found increased expression of TNF-α, IL-1β 
and IL-6 in a heterogeneous population of patients with heart failure (Gielen et al 
2003). A large proportion of the patients studied by Gielen et al had dilated, rather 
than ischaemic, cardiomyopathy, with no reported details regarding weight or body 
composition. 
 
TNF-α is also produced by adipose tissue (Kern et al, 1995). It has been proposed that 
TNF-α plays a key role in the depletion of adipose tissue mass in cachexia by 
promoting lipolysis and inhibiting lipogenesis (figure 1.2) (Warne et al, 2003). 
Argiles  et al argued that elevated circulating TNF-α levels, as opposed to local 
adipose tissue-derived TNF-α, is responsible for the metabolic alteration in adipose 
tissue in cachexia (Argiles et al, 1997). 
  27
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Figure 1.2. Proposed mechanisms by which TNF-α acts to decrease adipocyte 
mass.  Reproduced and modified from Warne et al, 2003. 
 
 
 Energy metabolism in cardiac cachexia 
Heart failure is associated with abnormal energy metabolism with decreased glucose 
oxidation and muscle glucose uptake, increased fat oxidation and levels of free fatty 
acids, and increased protein turnover (Norrelund et al, 2006). 
 
Having previously been thought to act simply as an energy store, adipose tissue is 
now known to have endocrine and paracrine functions, producing hormones 
important in the regulation of energy metabolism. There has been particular interest 
in the more recently discovered leptin and adiponectin. 
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Leptin is a hormone predominantly produced by adipose tissue, which decreases food 
intake and increases energy expenditure. Obese individuals have increased leptin 
levels, and after weight loss leptin levels decline (Lonnqvist F et al, 1995; Maffei et 
al, 1995; Considine et al, 1996). In experimental studies leptin administration has 
been shown to regulate the production of inflammatory cytokines, and in humans 
TNF-α infusion increases serum leptin levels (Loffreda et al, 1998; Zumbach et al, 
1997). It has therefore been suggested that leptin may play a role in the 
pathophysiology of cachexia. 
 
While leptin levels have been found to be low in cachectic heart failure, patients with 
non-cachectic advanced heart failure show significantly higher serum concentrations 
of leptin than patients with moderate exercise intolerance, suggesting possible 
involvement of leptin in the progressive catabolic state in heart failure (Murdoch et 
al, 1999; Filippatos et al, 2000). Furthermore, in these patients with non-cachectic 
advanced heart failure, a strong positive relationship was found between serum levels 
of leptin and TNF-α (Schulze et al, 2003). 
 
Adiponectin is a 244 amino-acid adipose tissue-specific peptide also thought to play 
an important role in the regulation of energy metabolism (Maeda et al, 1996; 
Chandran et al, 2003; Meier et al, 2004). In contrast to leptin, plasma adiponectin 
concentration is inversely correlated with body mass index and body fat in humans 
(Maeda et al, 1996; Chandran et al, 2003; Meier et al, 2004). Obesity is associated 
with reduced adiponectin levels, whereas levels are increased in anorexia nervosa 
(Iwahashi et al, 2003; Pannacciulli et al, 2003; Delporte et al, 2003). In experimental  29
animals, including genetically modified ones, administration of adiponectin reduces 
weight gain or leads to weight loss (depending on the model), possibly by increasing 
energy expenditure (Fruebis et al, 2001; Yamauchi et al, 2002; Masaki et al, 2003). 
 
Adiponectin is thought to have anti-inflammatory and anti-atherogenic effects. It has 
been reported to negatively correlate with C-reactive protein (CRP) in male subjects 
with coronary artery disease (Ouchi et al, 2003). TNF-α has been suggested to both 
increase and decrease adiponectin secretion (Bruun et al, 2003; Degawa-Yamauchi et 
al, 2005; Carey et al, 2006; Wang et al, 2006). Reduced adiponectin concentration 
has been found in patients with acute coronary syndromes, although the association 
between adiponectin levels and stable coronary artery disease or subsequent 
cardiovascular risk appears to be modest (Nakamara et al, 2004; Sattar et al, 2006).  
 
Adiponectin is also thought to regulate glucose and fatty acid metabolism, acting as 
an insulin sensitiser (Yamauchi et al, 2002; Wang et al, 2004). Levels of adiponectin 
are reduced in patients with type 2 diabetes mellitus (Hotta et al, 2000). 
 
Plasma adiponectin concentration has recently been shown to be increased in 
heterogeneous populations of patients with heart failure and to be an independent 
predictor of outcome (Kistorp et al, 2005; George et al, 2006). 
 
Natriuretic peptides in cardiac cachexia 
The significance of natriuretic peptides in heart failure with left ventricular systolic 
dysfunction has been extensively studied. B-type natriuretic peptide (BNP) is well  30
established as a strong predictor of outcome and marker of disease severity (Yu et al, 
1999; Troughton et al, 2000; Selvais et al, 2000; Berger et al, 2002, Lee et al, 2002). 
Although higher levels of BNP have been described in patients with more advanced 
heart failure, no relationship with cachexia has as yet been investigated. 
 
Lipolysis is thought to be predominantly regulated by the stimulatory action of the 
sympathetic nervous system and catecholamines, and the inhibitory action of insulin. 
Catecholamines, through binding to β-receptors on the surface of adipocytes, and via 
a cyclic adenosine monophosphate (cAMP) dependent pathway, result in the 
phosphorylation, and hence activation, of lipase. Recent studies have demonstrated 
that beta-blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers (ARB) prevent lipolysis and weight loss (Lainscak et al, 2006; 
Anker et al, 2003; Cabassi et al, 2006). 
 
Recently, a novel lipolytic and potential lipid-mobilising effect of natriuretic peptides 
has been identified (Sengenes et al, 2000). These actions appear to be mediated by 
specific adipocyte membrane receptors, which via a cyclic guanine monophosphate 
(cGMP) dependent pathway may indirectly stimulate adiponectin production. A role 
for BNP in the regulation of fat metabolism was supported by the recent finding by 
Horwich et al of an inverse relationship between BNP and BMI in patients with 
advanced heart failure (Horwich et al, 2006). Of further interest was the observation 
of Kistorp et al of a positive relationship between NT-proBNP and plasma 
adiponectin concentration in heart failure patients (Kistorp et al, 2005).  31
Skeletal Muscle Development, Injury and Repair  
Skeletal muscle consists of muscle fibres, which develop when myoblasts proliferate, 
fuse and differentiate into myocytes. Skeletal muscle terminally differentiates and is 
therefore unable to replicate. However, some myoblasts persist in a quiescent state 
under the basal lamina of the muscle fibre as satellite cells (Mauro et al, 1961). These 
satellite cells retain the ability to proliferate, providing a mechanism for muscle 
growth and repair (figure 1.3). Impairment of this proliferative potential will limit the 
ability of a muscle to repair following injury from mechanical, oxidative or 
inflammatory stress. The number of satellite cells, and this ability to replenish, 
declines with age (Bischoff et al, 1994). 
 
Figure 1.3. Regenerating muscle fibre. A) Queiscent satellite cell on basal lamina. B) 
Muscle fibre damage with satellite cell proliferation. C) and D) Myoblast fusion and 
differentiation into myocytes and myotubes. Diagram reproduced from unidentified source.  32
Satellite cells are activated by injury with a number of growth factors and cytokines 
involved in their proliferation, differentiation and chemotaxis (Chen et al, 1992; 
Tatsumi  et al, 1998; Bischoff et al, 1997). More recent work in mice has also 
suggested that the environment of growth factors and cytokines at an injury site may 
have a detrimental effect by triggering the differentiation of cells into various cell 
lineages, including myofibroblasts, leading to fibrosis and poor functional recovery 
(Li et al, 2002). 
 
Muscle development and regeneration is regulated at a molecular level by muscle 
regulatory factors (MRFs). This superfamily of transcription factors activate muscle 
specific genes. While quiescent satellite cells in rodent muscle do not express MRFs, 
when injured a fraction of satellite cells are activated, re-enter the cell cycle and 
express MRFs, before going on to differentiate, fuse and form muscle fibres (Grounds 
et al, 1992; Bischoff et al, 1986; Bischoff et al, 1994). 
 
The cell cycle is regulated by activation and inactivation of cyclin-dependent kinases 
(CDKs). Inhibitors of CDKs can prevent cells entering the cell cycle (by holding 
them in the gap phase) and thereby reduce their proliferative capacity. The Cip/Kip 
family of CDK inhibitors (p21, p27 and p57) are the most important and ubiquitous. 
When cultured myoblasts are induced to differentiate this results in the upregulation 
of inhibitors of the cell cycle, including the cyclin dependent kinase (CDK) inhibitors 
(Walsh et al, 1997). Activation of the CDK inhibitor genes is thought to be regulated 
by the muscle regulatory factor MyoD (Guo et al, 1995). 
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MyoD is present in low levels in adult skeletal muscle. Following injury there is 
increased expression by satellite cells. MyoD deficient muscle has impaired ability to 
regenerate after injury. The transcription factor NF-κB has a key role in the activation 
of genes involved in inflammatory and proliferative responses, and is activated itself 
by TNF-α. Work in mice has suggested that NF-κB, activated by TNF-α, acts as a 
mediator of cytokine induced muscle degeneration by suppressing the expression of 
MyoD (Guttridge et al, 2000). 
 
The molecular regulation of skeletal muscle wasting has been most extensively 
studied in sepsis, injury and cancer, with the mechanisms involved suspected to be 
similar in other catabolic conditions such as COPD and heart failure. A cascade of 
components and regulatory mechanisms appear to be involved in this complex 
pathway with gene expression of several components of the pathway known to be 
upregulated (Hasselgren et al, 2002).  34
Changes in Skeletal Muscle in Heart Failure 
The major symptomatic limitation experienced by heart failure patients is exercise 
intolerance caused by breathlessness and fatigue. The extent of exercise intolerance 
has been shown to be unrelated to the degree of central haemodynamic disturbance 
and is thought partly to be attributable to changes in skeletal muscle and reduction in 
skeletal muscle mass. 
 
Histological, metabolic, vascular perfusion, neurohumoral, inflammatory, and gene 
regulatory changes have been described in skeletal muscle of heart failure patients. 
There has been debate regarding whether these changes are related to heart failure per 
se or are due to disuse and deconditioning. Changes in skeletal muscle phenotype and 
the characteristics defining it￿s oxidative capacity (fibre type, oxidative enzymes, 
mitochondria, contractile proteins, capillary density) have been shown to relate to 
peak oxygen consumption and the degree of exercise intolerance (Wilson et al, 1993; 
Schaufeberger et al, 1995; Massie et al, 1996; Vescovo et al, 1996; Toth et al, 1997; 
Duscha et al, 2002; Drexler et al, 1992; Nicoletti et al, 2003).  35
Cachexia in Chronic Obstructive Pulmonary Disease 
It has been suggested that common pathogenic mechanisms underlie different 
cachectic states. As in heart failure, cachexia in COPD is associated with increased 
susceptibility to exacerbations of clinical symptoms and severely impaired functional 
capacity. As discussed earlier, cachexia has been defined in COPD as a body mass 
index (BMI) <23 kg/m
2 and a fat-free mass index (FFMI) <15 kg/m
2 in females and 
<16 kg/m
2 in males, with the emphasis on loss of fat free mass (muscle mass) 
(American Thoracic Society and European Respiratory Society, 1999). A recent 
small, single centre study applying a hybrid definition of cachexia, as an unintentional 
weight loss of ≥ 7.5% body weight over at least 6 months and a BMI ≤24 kg/m
2, 
found the prevalence of cachexia in COPD to be 33% (Koehler et al, 2006). 
 
As in heart failure, circulating TNF-α levels are elevated in patients with COPD, and 
even more markedly in the presence of cachexia (Di Francia et al, 1994; Takabatake 
et al, 2000). The presence of chronic hypoxia is thought to result in increased TNF-α 
production (Takabatake et al, 2000). 
 
COPD is associated with recurrent infective and non-infective exacerbations. It is 
thought that the associated acute systemic inflammatory response results in recurrent 
inflammatory insults and injury to the skeletal muscle. Similarly, heart failure is 
complicated by recurrent acute decompensations, and although the mechanism 
principally involves haemodynamic and neurohumoral changes, there is an associated 
rise in markers of systemic inflammation, suggesting that a similar mechanism of  36
recurrent acute inflammatory insults could contribute to muscle wasting in heart 
failure (Mueller et al, 2006). 
 
Our group, in investigating the molecular and cellular basis for skeletal muscle 
wasting in COPD, previously demonstrated that gene and protein expression of the 
cyclin dependent kinase (CDK) inhibitor p21 was increased in the skeletal muscle of 
COPD patients with cachexia (figure 1.4) (Fulds, 2004). We hypothesised that 
recurrent inflammatory insults in COPD resulted in muscle injury, and that local 
activation of cell cycle inhibitors impaired the muscles ability to repair. We further 
hypothesised that inflammatory cytokines act as a mediator of this process by 
influencing local gene expression. There are no previous studies of cell cycle 
inhibitor expression in the skeletal muscle of patients with heart failure. 
 
 
 
 
 
 
 
 
 
Figure 1.4. Western blots of relative expression of p21 protein in skeletal muscle 
of cachectic and non-cachectic COPD patients (Reproduced from Fulds, 2004). 
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Aim 
The aim of this doctoral work was to characterise the nature of cachexia in patients 
with heart failure and stable coronary artery disease, to quantify the loss of muscle 
mass, and test the hypothesis that muscle wasting is mediated by the activation of 
tissue cytokines and cell cycle inhibitors.  38
 
 
 
 
CHAPTER 2 
 
GENERAL METHODS  39
Subjects 
Subject recruitment 
Patients were recruited between December 2002 and July 2004 from the cardiology 
clinics of the North Glasgow University Hospitals and the primary care based heart 
failure nurse liaison service. Patient records were screened to identify subjects with 
heart failure (HF) and coronary artery disease (CAD) (with or without a history of 
weight loss), and a control group of patients with CAD but no heart failure. A large 
number of heart failure patients were screened to identify a population with cachexia. 
This was due to the relatively small proportion of heart failure patients with cachexia, 
a lack of awareness of cachexia as a prognostically important problem, and 
consequently the absence of regular body weight documentation in patient records, 
and the frailty of this patient population with the not inconsiderable demands of 
participating in the study. We specifically only studied patients with underlying 
coronary artery disease in order to control for differences in inflammatory activity 
related to differing aetiologies of heart failure. 
 
The study population was recruited to look at levels of gene expression in skeletal 
muscle and therefore the sample size was based on a power calculation using 
information from a previous study by our group looking at gene expression in skeletal 
muscle of patients with chronic obstructive pulmonary disease (COPD). We 
calculated that 7 patients in each group would give us a power of 0.80 to show a 
significant difference at the 5% level with a one-sided t-test given a 3-fold difference 
in expression of mRNA or protein being measured.  
  40
Age and activity matched healthy controls were recruited from patient companions at 
the clinics and a university staff advertisement. As previous studies in this area have 
involved heterogeneous populations of heart failure patients, a further control group 
of patients with dilated, rather than ischaemic, cardiomyopathy was recruited as an 
amendment to the study protocol. 
 
Following baseline assessment six patients with heart failure were found to have 
preserved left ventricular systolic function. One patient with heart failure and one 
patient with heart failure and cachexia withdrew consent. 
 
Subject groups 
We studied five groups of subjects. Three were groups of patients with stable 
coronary artery disease (CAD): 1) HF-cachexia - those with HF, reduced left 
ventricular systolic function and cachexia, n=10; 2) HF-no cachexia - those with HF, 
reduced systolic function but no cachexia, n=20; and 3) CAD - those with CAD, no 
symptoms of HF and preserved systolic function, n=10. The other subject groups 
were: 4) IDCM ￿ patients with dilated cardiomyopathy, n=7; and 5) Controls ￿ 
healthy controls, n=9. 
 
Skeletal muscle analysis was performed in a subgroup of subjects: HF-cachexia, n=7; 
HF-no cachexia, n=14; CAD, n = 5; healthy controls, n = 5. 
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The IDCM group were recruited as an amendment to the study protocol and 
underwent limited characterisation and blood analysis, and no skeletal muscle 
analysis. 
 
A further population of young healthy male subjects were specifically recruited for an 
additional study reported in chapter 6. 
 
Subject Characterisation 
Coronary artery disease (CAD): CAD was defined as a previously documented 
myocardial infarction or evidence of obstructive coronary artery disease on coronary 
angiography. 
 
Heart failure (HF): HF was defined using the European Society of Cardiology 
(ESC) Task Force and American College of Cardiology/American Heart Association 
(ACC/AHA) Guidelines as described previously in more detail in chapter 1 
(Swedberg et al, 2005; Hunt et al, 2005). 
 
Cachexia: As discussed in chapter 1, cachexia has previously been defined in a 
number of ways. The arbitrary definition devised by Anker et al, of cachexia as an 
unintentional weight loss of ≥ 7.5% body weight over at least 6 months, has been the 
most commonly used operational definition in recent heart failure studies and 
therefore was the definition we elected to use in this study (Anker et al, 1997). 
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Healthy controls: Healthy control subjects had no significant medical history or 
regular prescribed medication, and were age and activity-matched to the patient 
groups. 
 
Left ventricular function: Left ventricular ejection fraction (LVEF) was measured 
by radionucleotide ventriculography (RNVG). The LVEF was determined for all 
subjects using dual region of interest, except in the IDCM group in whom 
ventriculography had been performed prior to recruitment as part of an advanced 
heart failure assessment and LVEF determined using the single region of interest 
technique. RNVG is a reproducible method with inter-study variability of <5% and 
inter-observer variability reported to be as low as 2%. The technique used was 
equilibrium ventriculography which uses a sample of the patient￿s blood labelled with 
technetium (
99mTc) to produce a blood pool acquisition of several hundred summated 
beats, gated to the QRS complex, and acquired in a 45ß left anterior  oblique 
projection. Healthy volunteers <55 years of age had echocardiographic assessment of 
LVEF using the regional wall motion score. Administration of a radioisotope in this 
subject group was considered inappropriate after discussion with the Administration 
of Radioactive Substances Advisory Committee (ARSAC). 
 
Symptomatic status: Patients with HF had their degree of functional limitation 
quantified using the New York Heart Association (NYHA) classification. This system 
assigns patients to one of four functional classes, depending on the degree of effort 
needed to precipitate symptoms: patients may have symptoms of HF at rest (class IV), 
on less-than-ordinary exertion (class III), on ordinary exertion (class II), or only at  43
levels of exertion that would limit normal individuals (class I) (The Criteria 
Committee of the New York Heart Association, 1964). 
 
Cardio-respiratory exercise testing: Symptom limited cardio-respiratory treadmill 
exercise testing was performed as an objective assessment of functional capacity. All 
the tests were supervised by the same doctor and technician. Subjects were instructed 
to exercise until they felt unable to continue. Exhaled air was analysed to determine 
metabolic gas exchange with a metabolic cart. Oxygen uptake (VO2) and carbon 
dioxide production (VCO2) were determined on-line with breath-by-breath analysis. 
The peak VO2 was averaged over the last 30 seconds of exercise. The respiratory 
exchange ratio (RER) was determined as the ratio of VCO2/VO2   Rates of fat and 
carbohydrate oxidation were calculated using the stoichiometric equations of Frayn 
(Frayn, 1983). Continuous 12-lead ECG monitoring and heart rate and blood pressure 
response were recorded. 
 
The STEEP (Standardised Exponential Exercise Protocol) protocol was used (table 
2.1) (Northridge et al, 1990). This was devised as a single protocol suitable for 
subjects with a wide range of exercise capacities, which could be applied to a bicycle, 
or as in this study, the treadmill. As illustrated in the table the STEEP protocol 
employs one minute, stepwise increments in speed or gradient but never both 
simultaneously. The benefit of this protocol, particularly in patients with significant 
limitation in exercise capacity, is that smaller increments make it less likely that the 
subject will stop early following a transition of workload. In protocols with larger 
increments in workload subjects are more likely to stop within 5-10 seconds of a  44
change in stage, resulting in the grouping of the subjects duration of exercise rather 
than a spread of exercise capacity. We anticipated that this protocol would enable 
patients with HF to continue to a faster and steeper stage, possibly attaining a higher 
peak O2 consumption, producing a peak VO2 with improved reliability and prognostic 
value. Despite the advantages of this type of protocol it is important to note that 
patients with HF have slowed oxygen kinetics and therefore require time for O2 
consumption to reach near steady state (time provided by protocols with longer stages 
and larger increments but not by shorter stages and smaller increments) and therefore 
a steady state would never be achieved (Brunner-La Rocca, 1999)  
 
 
Time (min)  Speed (km h
-1) Slope  (%) 
1 2.4 0 
2 3.2 0 
3 3.2  1.5 
4 3.2  3.0 
5 4.0  3.0 
6 4.0  5.0 
7 4.0  7.0 
8 4.8  7.0 
9 4.8  9.0 
10 4.8  11.0 
11 5.6  11.0 
12 5.6  13.0 
13 5.6  16.0 
14 6.7  16.0 
15 8.0  16.0 
 
Table 2.1. STEEP (Standardised Exponential Exercise Protocol)  treadmill 
protocol (Northridge et al, 1990). 
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Body composition analysis: A weight history over the preceding 6 months or more 
was documented. Where there was uncertainty this was validated from hospital and 
heart failure nurse records. Body mass index (BMI) was calculated from body mass 
and height (Kg.m
-2). Waist circumference was measured using a flexible steel tape 
with the anatomical landmarks of midway
 between the lower rib cage and iliac crest,
 
and midway between the xiphoid process
 and the umbilicus. 
 
Body composition analysis can be performed using a number of techniques. The gold 
standard densitometry models using underwater weighing were felt inappropriate in 
the patient groups due to the cumbersome nature of this technique. Facilities for the 
dual-energy X-ray absorbitometry (DEXA) technique were not available. Percentage 
body fat and fat-free mass index (FFMI) were therefore determined using 
bioelectrical impedance analysis (BIA). Bioelectrical impedance was measured using 
a body composition analyser (TBF-300GS, Tanita Corp) with an operating frequency
 
of 50 kHz at 800 ￿A. All resistance measurements were adjusted
 for stature. The BIA 
system has been validated in healthy subjects against underwater weighing, DEXA, 
and tritium dilution volume methods, and more recently in stable heart failure patients 
against DEXA and deuterium dilution (Uszko-Lencer et al, 2006).  46
Blood Analysis 
Blood sampling and storage 
All subjects had a fasting blood sample taken between 9 and 10 am. Some blood was 
aliquoted to plain and ethylenediaminetetraacetic acid (EDTA) blood collection tubes 
and sent for same-day analysis by the Western Infirmary clinical biochemistry and 
haematology laboratories for urea, electrolytes, creatinine, albumin, haemoglobin, 
white cell count and platelets. Estimated glomerular filtration rate (eGFR) was 
calculated using the Modification of Diet in Renal Disease (MDRD) equation 
(O￿Meara et al, 2006). The rest of the blood was placed on ice, allowed to clot for 20 
minutes, and then centrifuged at 3000rpm for 15 minutes at 4°C. The serum or 
plasma was aliquoted to avoid subsequent freeze-thaw cycles and stored at -80°C 
until analysis. Blood for the measurement of plasma B-type natriuretic peptide (BNP) 
was collected in chilled tubes containing EDTA. 
 
Measurement of serum cytokines and adipokines 
Commercially available enzyme linked immunosorbent assay (ELISA) kits were used 
to measure serum concentrations of tumour necrosis factor-alpha (TNF-α), 
interleukin-6 (IL-6), adiponectin and leptin (Quantikine, R&D Systems). 
 
A monoclonal antibody specific for the protein being quantified is pre-coated onto a 
96-well microplate. Standards for a dilution curve were prepared. The standards and 
samples were pipetted into the wells and any of the protein present bound to the pre-
coated antibody. After washing away any unbound substances in the wells an 
enzyme-linked monoclonal antibody specific for the protein was added to the wells.  47
Following a further wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added with colour development in proportion to the amount of 
protein bound to the wells. The colour development reaction was stopped and the 
intensity of the colour measured. All samples, standards and controls were assayed in 
triplicate. The optical density of each well was determined within 30 minutes of 
stopping the reaction using an automatic microplate reader set to 450 nm. The mean 
for the triplicate readings for each standard, control, and sample was calculated. The 
optical density for the standards was plotted against their known concentrations and 
the best curve drawn. The data was linearised and the protein concentration 
determined for each sample by plotting the absorbance on the standard curve. 
 
Measurement of lipids and C-reactive protein 
Cholesterol, triglycerides, very low-density lipoprotein cholesterol (VLDL 
cholesterol), low-density lipoprotein cholesterol (LDL cholesterol), high-density 
lipoprotein cholesterol (HDL cholesterol) and C-reactive protein (CRP) 
concentrations were measured by enzymatic colorimetric methods using a Hitachi 
917 automated analyser (Roche kits). 
 
Fasting glucose, insulin and insulin resistance 
Fasting glucose and insulin were measured and the homeostasis model assessment 
(HOMA1-IR) index used to estimate insulin resistance (insulin resistance = (fasting 
glucose x fasting insulin)/22.5) (Matthews et al, 1985). 
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Measurement of plasma B-type natriuretic peptide (BNP) 
Plasma BNP was measured using the Shionoria immunoradiometric kit (Schering 
CIS, West Sussex, England). 49
Skeletal Muscle Analysis 
Percutaneous skeletal muscle biopsies 
Percutaneous needle biopsies were obtained from the vastus lateralis muscle from a 
subgroup of subjects using the technique described by Bergstrom (Bergstrom, 1975). 
With the subject supine, the lateral aspect of the thigh was infiltrated subcutaneously 
with local anaesthetic over the mid point of vastus lateralis. Using aseptic technique a 
5mm skin incision was made to allow passage of the Bergstrom needle through the 
subcutaneous fat and muscle capsule. Once in the muscle, tissue was aspirated 
through a side window into the hollow needle and excised. Haemostasis was 
established with light compression. The wound was covered with a sterile dressing. 
Feeling this was not an insignificant procedure for the study subjects to undergo, prior 
to commencement of the study, I myself had a muscle biopsy taken as a healthy 
control for another project in the department. All muscle biopsies were performed by 
myself. The biopsies were immediately snap frozen in liquid nitrogen and stored at 
−70￿C.  
 
Skeletal muscle histology 
A small sample of muscle was prepared on cork, frozen in isopentane-cooled liquid 
nitrogen and stored at ￿70￿C. Transverse sections were cut with a cryotome at ￿20￿C 
and stained for alkaline stable adenosine triphosphatase (ATP-ase) for identification 
of fibre types I, IIA and IIB. A specialist skeletal muscle histopathologist performed 
the examination of the biopsies. 
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Ribonucleic acid (RNA) extraction 
To process the stored muscle biopsies for RNA extraction the frozen samples were 
transferred to a liquid nitrogen-cooled mortar and pestle and ground to a fine powder 
under liquid nitrogen. The suspension (tissue powder and liquid nitrogen) was 
transferred into a liquid-nitrogen￿cooled 2 ml micro-centrifuge tube and the liquid 
nitrogen allowed to evaporate but without allowing the samples to thaw. 
 
For the extraction of RNA for reverse transcription and subsequent gene 
amplification with real-time polymerase chain reaction (RT-PCR) it was important to 
use a non-trizol based system. A fibrous tissue specific mini column kit (RNeasy 
Fibrous Tissue Mini Kit, Qiagen) was used. The recommended amount of starting 
tissue for RNA extraction from skeletal muscle using this technique is 30 mg. A 3 
mm cube of muscle powder, which for most tissues weighs 25￿35 mg, was therefore 
used. The manufacturers estimated yield is 5-10 ￿g RNA from 10 mg muscle tissue. 
The maximum binding capacity of the mini spin columns is 100 ￿g RNA and it was 
important that this was not exceeded or the yield of RNA would have been reduced. 
 
Disruption of the plasma membranes of cells and organelles with the mortar and 
pestle was required to release the RNA contained in the muscle sample. Lysis buffer 
(300  ￿l Buffer RLT) was added to the disrupted sample, which was then 
homogenized using a syringe and 20-gauge needle. Homogenization shears high-
molecular-weight genomic deoxyribonucleic acid (DNA) and other high molecular-
weight cellular components. 
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590 ￿l RNase-free water and 10 ￿l proteinase K solution were added to the 
homogenate and mixed thoroughly by pipetting. The sample was then incubated in a 
water bath at 55 ￿C for 10 min to allow proteinase K to remove proteins. 
 
The sample was centrifuged for 3 min at 10,000 g at 20￿25 ￿C with the debris 
forming a pellet. The supernatant (approximately 900 ￿l) was pipetted into a new 1.5 
ml micro-centrifuge tube. 0.5 volumes of ethanol (100%, approximately 450 ￿l) was 
added to the sample and mixed well by pipetting. The RNeasy Mini Spin Column, 
which contains a silica gel membrane for RNA binding, was placed in a 2ml 
collection tube. 700 ￿l of the sample was pipetted into the column and centrifuged 
through at 8000 g (10,000 rpm) for 15 sec and the flow-through discarded. This step 
was repeated with the remainder of the sample. The column and membrane was then 
washed with Buffer RW1 (350 ￿l) by centrifugation for 15 sec at 8000 g and again 
the flow-through discarded. 
 
Traces of DNA may co-purify to the membrane and therefore, on-column DNase 
digestion was performed by mixing RNase-free DNase I (10 ￿l) with Buffer RDD (70 
￿l) and pipetting the mixture directly onto the membrane. The column was incubated 
on the bench top at room temperature for 15 min. Following the incubation, the 
column was again washed with Buffer RW1 (350 ￿l) to remove the DNase and 
contaminants by centrifuging for 15 sec at 8000 g and discarding the flow-through. 
 
The column was then transferred into a new 2 ml collection tube. Two further washes 
were performed using Buffer RPE (500 ￿l), the first with centrifugation for 15 sec at  52
8000 g and the second for 2 min at 8000 g. The column was then transferred to 
another 2 ml collection tube and centrifuged at 10,000 g for 1 min to ensure the 
membrane was completely dried. This was important to ensure that no ethanol was 
carried over to the RNA elution. 
 
To elute the RNA from the membrane the column was transferred to a new 1.5 ml 
collection tube. 30 ￿l RNase-free water was pipetted directly onto the membrane and 
the tube centrifuged for 1 min at 8000 g. This step was repeated adding a further 30 
￿l RNase-free water and centrifuging for a further 1 min. 
 
Purified RNA was stored at ￿80 ￿C. The concentration of the RNA was determined 
by measuring the absorbance at 260 nm in a spectrophotometer. For this process the 
RNA samples were diluted (10 ￿l of RNA sample plus 490 ￿l of RNase-free water 
(1/50 dilution) and the absorbance measured in a 1 ml cuvette. An absorbance of 1 
unit at 260 nm corresponds to 44 ￿g of RNA per ml. 
 
Complementary DNA (cDNA) synthesis  
Samples for subsequent RT-PCR were all reverse transcribed using the iScript cDNA 
synthesis kit (BioRad). The iScript reverse transcriptase is RNase H
+. It is premixed 
with an RNase inhibitor, to prevent degradation of the RNA template, and a blend of 
oligo(dT) and random primers. The reaction composition and protocol used are 
outlined in table 2.2. 
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Reaction Set Up  Volume 
5x iScript Reaction Mix  4￿l 
iScript Reverse Transcriptase  1￿l 
Nuclease-free water  X￿l 
RNA template  X￿l 
Total volume  20￿l 
Reaction Protocol   
5 minutes at 25ßC  
30 minutes at 42ßC  
5 minutes at 85ßC  
Hold at 4ßC  
 
Table 2.2. Complementary DNA synthesis.  54
Relative quantification of messenger RNA (mRNA) using real-time polymerase chain 
reaction (RT-PCR) 
RT-PCR, by measuring product during the exponential phase of the reaction, can 
detect two-fold changes, while traditional PCR, by measuring product during the 
plateau phase once the reaction has stopped and product is degrading, can only detect 
ten-fold changes (figure 2.1).  
 
 
 
Figure 2.1. PCR amplification curve (Modified image from www.inra.fr). 
 
We performed relative quantification of mRNA for our genes of interest using the 
iCycler iQ RT-PCR detection system (Bio-Rad). This is a 96-well plate set up with 
fluorescent detection during the exponential phase of target gene amplification. The 
threshold cycle is the point at which the reaction reached a fluorescent intensity above 
background. 
Reaction most efficient and 
accurate 
Reaction slowing 
as components 
run out 
Reaction stops 
and product 
degradation  55
 
Primer design 
Primers were designed using the NCBI gene database and Primer 3 software. The 
following parameters were used: 
  Amplify a template 75-150 bp 
  Aim for a GC content of 50-60 % 
  Avoid G or C repeats longer than 3 bases 
  Place G￿s and C￿s on the ends of primers 
  Aim for a melting temperature (Tm) of 50-65 ßC 
Avoid complementarity between the forward and reverse primers (to avoid 
primer-dimer formation) 
  Avoid secondary structures 
  Verify specificity using Basic Local Alignment Search Tool (BLAST) 
 
For some of the target genes we also used previously published primers to verify 
results. We analysed skeletal muscle expression of message for inflammatory 
cytokines (TNF-α, IL-1β, IL-6 and IL-18) and the cyclin dependent kinase (CDK) 
inhibitors (p21, p27 and p57). The primers used are listed in table 2.3. 
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Primer  Sequence 5￿ to 3￿ 
Β-actin Forward  GAC AGG ATG CAG AAG GAG ATT ACT 
Β-actin Reverse  TGA TCC ACA TCT GCT GGA AGG T 
18S rRNA Forward  TAG AGG GAC AAG TGG CGT TC 
18S rRNA Reverse  TGT ACA AAG GGC AGG GAC TT 
B2M Forward  ATG AGT ATG CCT GCC GTG TGA 
B2M Reverse  GGC ATC TTC AAA CCT CCA TG 
CYC Forward  CCC ACC GTG TTC TTC GAC AT 
CYC Reverse  CCA GTG CTC AGA GCA CGA AA 
GAPDH Forward  CCA CCC ATG GCA AAT TCC 
GAPDH Reverse  TGG GAT TTC CAT TGA TGA CAA 
TNFα Forward  TGT GTT GTC CTT CCT GCA AC 
TNFα Reverse  CTT GTA GGT GCC CAG GAG AG 
IL-1β Forward  GGA CAA GCT GAG GAA GAT GC 
IL-1β Reverse  TCG TTA TCC CAT GTG TCG AA 
IL-6 Forward  AGC CCT GAG AAA GGA GAC ATG TA 
IL-6 Reverse  CAT CTT TGG AAG GTT CAG GTT GT 
IL-18 Forward  GGA ATT GTC TCC CAG TGC AT 
IL-18 Reverse  GAA GCG ATC TGG AAG GTC TG 
P21 Forward  ATG AAA TTC ACC CCC TTT C 
P21 Reverse  CCC TAG GCT GTG CTC ACT T 
P27 Forward  GGC TAA CTC TGA GGA CAC GC 
P27 Reverse  TTG CAG GTC GCT TCC TTA TT 
P57 Forward  TCG CTG TCC TCT CCT CTC TC 
P57 Reverse  GCG CAC TAG TAC TGG GAA GG 
 
Table 2.3. Primer sequences.  57
Reaction components and protocols 
We used the iQ SYBR Green Supermix (100 mM KCl, 40 mM Tris-HCI, pH 8.4, 0.4 
mM of each dNTP (dATP, dCTP, dGTP, and dTTP), iTaq DNA polymerase, 50 
units/ml, 6 mM MgCl2, SYBR Green I, 20 nM fluorescein, and stabilizers). SYBR 
green binds to double stranded DNA (dsDNA) product with detectable fluorescence 
increasing as the amount of product increases. The iTaq DNA polymerase is a hot-
start enzyme activated by an initial 3 min denaturation step at 95 ￿C. This prevents 
non-specific amplification during plate preparation. 
 
The reaction composition and a typical protocol are outlined in table 2.4. After the 
initial hot start step to activated the DNA polymerase a 2-step cycle of amplification 
with 50 repeats was used. Fluorescence was measured automatically at the end of step 
2. Figure 2.1 shows an example of an amplification curve. 
 
Reaction Set Up  Volume      
IQ SYBR Green Supermix  12.5￿l         
Forward Primer  0.5￿l         
Reverse Primer  0.5￿l         
Sterile water  8.5￿l         
CDNA template  3￿l         
Total Volume  25￿l         
Protocol  Repeats  Step    Time Temp 
Hot start  1  1    3 min  95ßC 
Amplification  2 50 1  10  sec  95ßC 
     2  45  sec  60ßC 
Melt curve  3  1    1 min  95ßC 
 4  1    1  min  55ßC 
 5  80    10  sec  55ßC 
 
Table 2.4. Real Time Polymerase Chain Reaction (RT-PCR) Protocol.  58
 
Figure 2.2. Example of target gene and housekeeping gene amplification curve. 
 
After amplification was complete, the reaction was stopped, and the temperature of 
the samples reduced to 55 ßC. The temperature was then increased by 0.5 ßC every 10 
seconds until the product of the reaction melted. All products from a particular primer 
should melt at the same temperature allowing the identification of any contaminating 
products such as primer-dimers. Figure 2.2 shows an example of a desirable melt 
curve. 
 
To optimise the annealing temperature for primers a gradient protocol was performed. 
This involved a protocol similar to that illustrated in table 2.4 but with a 10 ßC range 
of annealing temperatures applied down the rows of the plate (ie. Annealing at 50 ßC 
in row A, 51.25 ßC in row B, 52.5 ßC in row C, increasing to 60 ßC in row H) to 
identify which annealing temperature resulted in optimal amplification.  59
 
Figure 2.3. Target and housekeeping gene amplification product melt curves. 
 
Target gene expression was measured relative to the expression of a house keeping 
gene. Each sample was run in triplicate for both the target and housekeeping gene 
amplifications. The threshold cycles of the triplicates were averaged and the quantity 
of the target gene expressed relative to the housekeeping gene for each sample in 
relative units. 
 
Housekeeping gene 
The selection of a housekeeping gene against which the relative expression of the 
target genes could be measured in skeletal muscle was problematic. The most 
commonly used housekeeping genes are muscle derived due to the usual stability of 
their expression. We selected beta-actin (β-actin), which has previously been widely 
used. We were concerned that the expression of β-actin would be altered (and most 
likely up-regulated) in the presence of inflammation in skeletal muscle and that this 
may mask any up-regulation in expression of the genes of interest.   60
 
In the absence of an ￿ideal￿ house-keeping gene against which changes in target gene 
expression in skeletal muscle could be measured, we addressed this potential problem 
by selecting four further established house-keeping genes to allow comparisons of 
relative expression (CYC, B2M, GADPH and 18S ribosomal RNA). The 18S rRNA 
has previously been used to look at relative expression of inflammatory mediators in 
skeletal muscle (Gielen et al, 2003).  The expression of TNFα was calculated relative 
to the expression of CYC, B2M, GADPH, and 18S ribosomal RNA in addition to β-
actin.  There was no between group difference in TNFα mRNA expression when 
calculated relative to each of the house-keeping genes.    61
Protein quantification using western blotting 
Sample preparation  
The disrupted muscle biopsy samples (tissue powder) were lysed and homogenised 
with a lysis buffer (120 ￿l) (table 2.5) plus protease inhibitor cocktail (1 tablet/10 mls 
lysis buffer) and using a syringe and 20-gauge needle. 
 
Tris HCl (pH 7.4)  50mM  100mls of 100mM 
EDTA  1mM  2mls of 100mM 
DTT 50mM   
SDS  0.1%  2mls of 10% 
Igepal 0.5%  1mls 
Total volume    200mls 
 
Table 2.5. Lysis buffer for preparation of muscle samples. 
 
The protein concentration of the samples was determined using the Protein Assay 
ESL kit (Roche). A series of standard samples were prepared with a BSA protein 
standard (2 mg/ml) (table 2.6). The biopsy samples were diluted by adding 10 ￿l of 
sample to 190 ￿l lysis buffer (1:20 dilution). 50 ￿l of each of the standards and 
samples were added to a series of 1.5 ml cuvettes containing100 ￿l of Reagent A. 
After mixing they were incubated at room temperature for at least 5 minutes. Taking 
each cuvette in turn, 1000 ￿l of Reagent B was added, mixed, and absorbance 
measured at 485 nm against a lysis buffer zero reference, at exactly 30 seconds. A 
standard curve of absorbance versus concentration was plotted and from this the 
protein concentration of the samples was calculated (x 20 dilution). The same 
standard curve was used for all samples validating it on each occasion with the 
absorbance for standard 1.  62
 
Standard  Lysis buffer  BSA protein 
standard 
Concentration 
1 400￿l 0￿l 0￿g/ml 
2 390￿l 10￿l 50￿g/ml 
3 380￿l 20￿l 100￿g/ml 
4 340￿l 60￿l 300￿g/ml 
5 300￿l 100￿l 500￿g/ml 
6 250￿l 150￿l 750￿g/ml 
 
Table 2.6. Preparation of standard samples for protein quantification. 
 
60 ￿g of protein was used for each sample. Each sample was diluted at least 1:2 with 
sample buffer (table 2.7) plus β-mercaptoethanol (475 ￿l sample buffer plus 25 ￿l β-
ME) to a maximum loading volume of 25 ￿l. The diluted samples and a protein 
ladder (15 ￿l) were incubated at 95  C for 5 minutes. 
 
dH2O 3.55ml 
0.5M Tris-HCl (pH 6.8)  1.25ml 
Glycerol 2.5ml 
10% SDS  2.0ml 
0.5% bromophenol blue  0.2ml 
Total volume  9.5ml 
 
Table 2.7. Sample buffer preparation. 
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Protein separation 
Protein separation was performed using polyacrylamide gel electrophoresis with the 
SDS-PAGE (Laemmli) Discontinuous Buffer System. This system denatures proteins 
by heating them in buffer containing sodium dodecyl sulfate (SDS) and 2-
mercaptoethanol (βME). The resultant polypeptides separate according to their 
molecular weights. 
 
Gel preparation and formulation: A glass plate sandwich with casting frame and 
stand (Mini-PROTEAN 3, BioRad) was used to cast the gels. 10% resolving gels and 
4% stacking gels were used (table 2.8). The resolving gel buffer was 1.5 M Tris-HCl 
(pH 8.8) and stacking gel buffer 0.5 M Tris-HCl (pH 6.8). 
 
After the 10% resolving gel was prepared as shown in table 2.9, 10% APS (50 ￿l) and 
TEMED (5 ￿l) were added to the gel immediately prior to pipetting. The mixture was 
swirled gently to initiate polymerisation. The resolving gel solution was pipetted to 1 
cm below the level reached by the stacking gel comb teeth, and immediately overlaid 
with dH2O. The gel was left for 45 minutes to polymerise, after which the dH2O was 
removed. 
 
The 4% stacking gel was then prepared as shown in table 2.8 and, as for the resolving 
gel, 10% APS (50 ￿l) and TEMED (10 ￿l) were added just prior to pipetting. The 
stacking gel solution was pipetted directly on top of the resolving gel until the top of  64
the short plate was reached. The comb was then inserted and the gel left for 45 
minutes to polymerise, after which the comb was removed. 
 
% gel  DH2O  30%Acrylamide/Bis  Gel Buffer  10% SDS 
10% 4.1ml  3.3ml  2.5ml  0.1ml 
4% 6.1ml  1.3ml  2.5ml  0.1ml 
 
Table 2.8. Resolving and stacking gels for protein separation. 
 
Tris 25mM  3.94g 
Glycine 192mM (20% methanol)  14.4g 
Dissolve in dH2O  
Add 200ml of methanol   
Adjust volume to 1000ml with dH2O  
 
Table 2.9. Towbin buffer for protein transfer. 
 
Electrophoresis: The gel cassette sandwich was removed from the casting stand and 
frame and transferred to the electrophoresis module. It was placed on the electrode 
assembly and then together they were slid into the clamping frame. The assembled 
inner chamber was then placed into a mini-tank. 
 
Electrophoresis running buffer was prepared by diluting stock solution (10 x 
Tris/Glycine/SDS, 50 ml in 450 mls dH2O). The inner chamber was filled with the 
buffer until the level was half way between the tops of the short and long plates 
(approximately 125 ml) and approximately 200 ml of the buffer was added to the 
mini-tank.  65
The samples were loaded slowly into the wells using a loading guide and pipette with 
gel loading tips. The gel was then run at 200 V for 35 minutes 
 
Protein transfer 
After electrophoresis was complete the inner chamber was removed, running buffer 
discarded, and the gel cassette sandwich removed. The gel was then removed from 
the sandwich by gentle prising apart the glass plates and removing the larger plate 
using the gel releaser tool. After cleaving the stacking gel section the gel and plate 
were soaked in pre-chilled towbin transfer buffer (500 ml) for 15 minutes to allow 
equilibration (table 2.9). 
 
A nitrocellulose transfer membrane and blotting paper (x 3) were cut to the 
dimensions of the gel (8.3 x 5 cm) always handling with forceps or gloves. The 
membrane was soaked briefly in methanol and then in towbin transfer buffer for 15-
30 minutes, sliding the membrane in slowly to avoid traping air bubbles. After 
saturating briefly in towbin a blot was placed on the transfer plate (Trans-Blot SD 
semi-dry electrophoretic transfer cell). A pipet was rolled over the surface of the 
paper to remove any trapped air bubbles. The membrane was overlaid and any air 
bubbles rolled away. The gel was then floated off the small glass plate by agitating 
gently and placed onto the membrane, and any air bubbles rolled away. The other 2 
blots were briefly soaked in the towbin and then placed on top, again rolling away 
any air bubbles between each layer. The gel was transferred at 15 V for 30 minutes. 
The membrane was then removed rinsed twice and soaked in phosphate buffered 
saline (PBS) (table 2.10).  66
KH2PO4 0.144g  1.06mM 
K2HPO47H2O   0.795g  2.96mM 
NaCl 9.00g  155mM 
Dissolved in 800ml dH2O    
PH adjusted to 7.4     
Dilute to 1000ml with dH2O and autoclave     
 
Table 2.10. Phosphate buffered saline (PBS) for protein detection. 
 
Protein detection 
The primary antibody for specific protein detection was reconstituted in 500 ￿l PBS 
to a concentration of 1 ￿g/￿l. The transfer membrane was incubated in a blocking 
agent (100 ml PBS plus 3-5% powdered milk), for at least 30 minutes at room 
temperature (or overnight at 4   C) with constant agitation, to block non-specific 
protein binding sites. The antibody was diluted 1:1000 in the blocking agent (30 ￿l in 
30 ml), and the membrane incubated in this solution for a further 1.5-2 hours at room 
temperature (or overnight at 4  C) with constant agitation. The membrane was then 
washed 5 times for 5 minutes with wash buffer (250 ml PBS plus 125 ￿l Tween) with 
constant agitation. The primary antibodies used were monoclonal anti-human TNF-α 
antibody, monoclonal anti-human IL-1β antibody, monoclonal anti-human IL-6 
antibody, and monoclonal anti-human p21 antibody (R&D Systems). 
 
The secondary antibody (Goat anti-Mouse IgG, Upstate), conjugated to the enzyme 
horseradish peroxidase (HRP), was reconstituted and diluted 1:1000 in the blocking 
agent. The membrane was then incubated in this solution for 1 hour at room  67
temperature (or overnight at 4  C) with constant agitation. The membrane was washed 
a further 5 times with wash buffer and then rinsed quickly 5 times with dH2O. 
 
Chemiluminescent HRP substrate luminol reagent (LumiGLO, Upstate) was prepared 
by combining 2.5 ml of substrate solutions A and B protecting the reagent from light 
and allowing to warm to room temperature. The membrane was transferred to a fresh 
tray with forceps and the LumiGLO added, incubating for 1 minute at room 
temperature. The membrane was removed, excess reagent drained by touching the 
corner to filter paper, and placed in a film exposure folder, ensuring there were no air 
bubbles between the membrane and folder. The folder was placed in an X-ray film 
exposure cassette. The X-ray film was then exposed to the membrane in a dark room 
(exposure time varying from a few seconds to a few minutes) and the film developed.  68
Statistical Techniques 
GraphPad Instat (GraphPad Software Inc., San Diego, USA) software was used for all 
statistical calculations.    
 
Mean and medians 
Results are expressed as mean (SD) for subject characteristics and median (range) for 
biomarkers. Normality testing was performed and parametric or non-parametric tests 
were then used as appropriate. Data not normally distributed was log transformed to 
allow parametric testing where appropriate . Two-sided tests of significance were 
used. Statistical significance was taken at the 5% level. 
 
Comparisons 
Differences between groups were assessed using one-way analysis of variance 
(ANOVA) or Kruskal-Wallis non-parametric ANOVA. Bartlett￿s test for 
homogeneity of variance was performed. Where differences were identified a 
Dunnett￿s (parametric) or Dunn￿s (non-parametric) multiple comparison post-hoc test 
was performed. Fisher￿s exact test was used to compare categorical characteristics. 
 
Correlations 
The data was logarithmically transformed for linear regression analysis and Run￿s test 
used for departure from linearity. Relationships were further assessed by multiple 
linear regression analysis allowing adjustment for multiple relevant factors.  69
 
 
 
 
CHAPTER 3 
 
THE DEVELOPMENT OF CACHEXIA IN HEART FAILURE 
PREDOMINANTLY INVOLVES THE LOSS OF FAT WITH THE 
RELATIVE PRESERVATION OF SKELETAL MUSCLE AND BONE 
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Introduction 
Although cachexia has been identified as a prognostically important development in 
patients with heart failure, its definition and pathophysiology remain the subject of 
debate (Von Haehling et al, 2007). 
 
As discussed in the preceding chapters, the most commonly used definition of 
cachexia in recent heart failure studies has been the involuntary loss of a percentage 
of body weight over a fixed period of time (Anker et al, 1997). In the absence of 
detailed information regarding body composition it has commonly been assumed that 
muscle wasting is the major contributor to this weight loss. 
 
One of the most frequently postulated causes of cachexia is cytokine activation and, 
in particular, increased production of tumour necrosis factor alpha (TNFα). Ageing, 
muscular dystrophy, and other chronic diseases have been associated with activation 
of cell cycle inhibitors (cyclin dependent kinase (CDK) inhibitors), resulting in 
impaired proliferation of muscle progenitor cells and muscle repair (Welle et al, 
2004; Endesfelder et al, 2000; Dasarathy et al, 2004; Fulds, 2004). We hypothesised 
that the presence of more markedly elevated levels of circulating cytokines in cardiac 
cachexia would be associated with increased muscle cytokine expression. We further 
hypothesised that activation of CDK inhibitors in skeletal muscle, possibly under the 
regulation of the inflammatory cytokines, may also be involved in the development of 
cardiac cachexia. 
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To further investigate the nature and pathogenesis of cardiac cachexia we assessed 
body composition and measured circulating levels of inflammatory cytokines, and 
skeletal muscle expression of cytokines and cell cycle inhibitors in a well 
characterised population of heart failure patients with and without cachexia. 
 
In order to control for differences in cytokine activation and inflammatory activity 
related to differing aetiologies of heart failure, we specifically only studied patients 
with underlying coronary artery disease. We also studied a control group with stable 
coronary artery disease, with normal ventricular function and without heart failure, as 
well as a group with idiopathic dilated cardiomyopathy, and healthy controls.   72
Methods 
Subject recruitment 
As discussed in more detail in chapter 2, subjects were recruited between December 
2002 and July 2004 from cardiology clinics at the North Glasgow University 
Hospitals and the primary care based heart failure nurse liaison service. Patient 
records were screened to identify subjects with heart failure (HF) and coronary artery 
disease (CAD), with or without a history of weight loss, a control group with CAD 
but no HF, and a group with idiopathic dilated cardiomyopathy (IDCM). Age and 
activity matched healthy controls were recruited from patient companions at the 
clinics and a university staff advertisement. Informed written consent was obtained 
from all participants and the study approved by the local ethics committee.  
 
For recruitment, cachexia was defined as an unintentional weight loss of ≥ 7.5% body 
weight over ≥6 months (Anker et  al, 1997). CAD was defined as a documented 
myocardial infarction or the presence of coronary artery disease on coronary 
angiography. 
 
Subject groups 
Five groups of subjects were studied. Three were groups of patients with stable 
coronary artery disease (CAD): 1) HF-cachexia - patients with CAD, heart failure 
(HF), reduced left ventricular (LV) systolic function and cachexia, n=10; 2) HF-no 
cachexia - those with CAD, HF, reduced LV systolic function but no cachexia, n=20; 
and 3) CAD - those with CAD, but no symptoms of HF and preserved LV systolic  73
function, n=10. The other subject groups were: 4)  IDCM - patients with dilated 
cardiomyopathy, n=7; and 5) HC - healthy controls, n=9. 
 
Heart failure characterisation and body morphology 
Subjects were characterised by New York Heart Association (NYHA) classification, 
left ventricular ejection fraction (LVEF) and peak oxygen consumption (VO2), 
obtained from symptom limited treadmill stress testing using the STEEP 
(Standardised Exponential Exercise Protocol) protocol (Northridge et al, 1990). The 
details of subject characterisation were previously discussed in detail in chapter 2. 
Co-morbidity and drug therapy were recorded.  
 
A weight history, body mass index (BMI) and waist circumference were documented. 
Percentage body fat and fat free mass index (FFMI) were determined using 
bioelectrical impedance (BIA) with a body composition analyser (TBF-300GS, Tanita 
Corp).  
 
Characterisation of the IDCM group was performed during advanced heart failure 
assessment as an amendment to the study protocol and was limited. 
 
Blood sample collection and analysis 
All subjects had fasting blood samples taken between 9 and 10am. Blood samples 
were placed on ice, allowed to clot for 20 minutes and then centrifuged at 3000 rpm 
for 15 minutes at 4°C. The serum or plasma was aliquoted and stored at -80°C until 
analysis. Serum tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were  74
measured in triplicate using commercially available enzyme-linked immunosorbent 
assay (ELISA) kits (Quantikines, R&D systems). C-reactive protein (CRP) 
concentration was measured using a Hitachi 917 analyser (Roche). The methods used 
have been described in more detail in chapter 2. 
 
Skeletal muscle analysis 
Skeletal muscle analysis was performed in a subgroup of subjects: HF-cachexia, n=7; 
HF-no cachexia, n=14; CAD, n = 5; controls, n = 5. Percutaneous needle biopsies 
were obtained from the middle part of the vastus lateralis muscle using the Bergstrom 
technique (Bergstrom, 1975). The biopsies were snap frozen in liquid nitrogen 
immediately after they were excised and stored at −80￿C until analysed.  
 
A small sample of muscle was prepared on cork, frozen in isopentane-cooled liquid 
nitrogen and stored at ￿70￿C. Transverse sections were cut with a cryotome at ￿20￿C 
and stained for alkaline stable adenosine triphosphatase (ATP-ase) for identification 
of fibre type composition. Percentage area of type I, IIA, and IIB fibres, fibre 
thickness and muscle area (expressed as a percentage of the microscopic field) were 
analysed by a skeletal muscle pathologist. 
 
Ribonucleic acid (RNA) was extracted from the skeletal muscle using a commercially 
available kit (RNeasy Fibrous Tissue Mini Kit, Qiagen). The RNA was reverse 
transcribed to produce complementary deoxyribonucleic acid (cDNA) (iScript cDNA 
synthesis kit, BioRad). Real-Time Polymerase Chain Reaction (RT-PCR) was used to 
relatively quantify the expression of cytokine messenger RNA (mRNA) in skeletal  75
muscle (BioRad iCycler iQ RT-PCR detection system with iQ SYBR Green 
Supermix). Primers were designed using the NCBI gene database and Primer 3 
software (table 3.1). Cytokine and CDK inhibitor gene expression were measured 
relative to expression of the housekeeping gene β-actin. Samples were run in 
triplicate for both the target and housekeeping gene amplifications. The threshold 
cycles of the triplicates were averaged and the quantity of the target gene expressed as 
a ratio relative to the housekeeping gene for each sample.   
 
 
Primer  Sequence 5￿ to 3￿ 
Β-actin Forward  GAC AGG ATG CAG AAG GAG ATT ACT 
Β-actin Reverse  TGA TCC ACA TCT GCT GGA AGG T 
TNFα Forward  TGT GTT GTC CTT CCT GCA AC 
TNFα Reverse  CTT GTA GGT GCC CAG GAG AG 
IL-1β Forward  GGA CAA GCT GAG GAA GAT GC 
IL-1β Reverse  TCG TTA TCC CAT GTG TCG AA 
IL-6 Forward  AGC CCT GAG AAA GGA GAC ATG TA 
IL-6 Reverse  CAT CTT TGG AAG GTT CAG GTT GT 
IL-18 Forward  GGA ATT GTC TCC CAG TGC AT 
IL-18 Reverse  GAA GCG ATC TGG AAG GTC TG 
p21 Forward  ATG AAA TTC ACC CCC TTT C 
p21 Reverse  CCC TAG GCT GTG CTC ACT T 
p27 Forward  GGC TAA CTC TGA GGA CAC GC 
p27 Reverse  TTG CAG GTC GCT TCC TTA TT 
p57 Forward  TCG CTG TCC TCT CCT CTC TC 
p57 Reverse  GCG CAC TAG TAC TGG GAA GG 
 
Table 3.1. Primer sequences. 
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Cytokine and CDK inhibitor protein quantification was performed in a selection of 
skeletal muscle samples using the western blotting technique. 
 
The methods used for skeletal muscle analysis have been described in more detail in 
chapter 2. 
 
Statistical analysis 
Subject characteristics and measures of body morphology are expressed as mean 
(SD). Biomarkers are expressed as median (range). Normality testing and Bartlett￿s 
test for homogeneity of variance were performed and differences between groups 
were assessed by one-way analysis of variance (ANOVA) or Kruskal-Wallis non-
parametric ANOVA. Where differences were identified Dunnett￿s or Dunn￿s multiple 
comparison post hoc test was performed. Fisher￿s exact test was used to compare 
categorical characteristics. The data was logarithmically transformed for linear 
regression analysis and a Run￿s test used for departure from linearity. Relationships 
were further assessed by multiple linear regression analysis adjusting for age, peak 
VO2, LVEF, and estimated glomerular filtration rate (eGFR). Statistical significance 
was taken at the 5% level. 
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Results 
Subject characteristics 
Patients with HF-cachexia were older than the other subjects, but the difference was 
only significant in comparison to the IDCM group (table 3.2). The HF-cachexia group 
had worse functional class and lower peak VO2 than the HF-no cachexia group. The 
IDCM group had better functional class, but lower peak VO2 than the HF-cachexia 
group, although neither difference was significant. LVEF and peak VO2 were lower 
in patients with HF (HF-cachexia and HF-no cachexia groups) than CAD patients and 
healthy controls.  
 
Patients with HF-cachexia had the shortest duration of exercise: HF-cachexia 124.6 
(101) seconds, HF-no cachexia 580.3 (327.4) seconds, CAD 585.6 (178.6) seconds, 
and HC 674 (214.6) seconds (p<0.01 for HF-cachexia compared to each other group) 
(figure 3.1). In patients with HF (HF-cachexia and HF-no cachexia groups), duration 
of exercise was lower in those with NYHA class IV than in those with NYHA class 
III or II symptoms: NYHA class IV 40.7 (20.2) seconds, NYHA class III 280.9 
(206.2) seconds, and NYHA class II 750 (282.1) seconds (p<0.01 for NYHA IV 
compared to NYHA III and II) (figure 3.2). 
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  HF-cachexia
(n=10)  
HF-no 
cachexia 
(n=20) 
CAD 
(n=10) 
 IDCM 
(n=7) 
HC  
(n=9) 
Mean age  
(years) 
72.7 67.6 64.4  52.4
** 59 
Gender 
(M/F) 
8/2  18/2  9/1 6/1 4/5 
NYHA 
II/III/IV 
0/7/3  12/8/0  -    5/2/0  - 
LVEF  
(%) 
27.1 (11.9)  35.4 (9.7)  73.0 (6.4)
 **  15.0 (4.0)    68.8(5.4)
** 
Peak VO2 
(mL/min/Kg)
9.8 (2.3)  13.6 (3.9)
 * 21.2  (2.0)
 ￿￿ 9.2  (2.0) 26.8  (5.0)
 ￿￿ 
 
Table 3.2 Subject characteristics. LVEF (%) measured using dual region of interest 
(normal ≥55%), except IDCM group where single region of interest technique used (normal 
≥40%). Differences between groups assessed by ANOVA or Kruskal-Wallis ANOVA. Post 
hoc analysis with Dunnett￿s or Dunn￿s multiple comparisons. Categorical characteristics 
compared with Fisher￿s exact test. For HF-cachexia vs each other group: *p<0.05, **p<0.01, 
***p<0.005, 
￿p<0.001, 
￿￿p<0.001. 
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Figure 3.1. Duration of exercise by subject group. Differences between groups 
assessed by ANOVA. Post hoc analysis with Dunnett￿s multiple comparisons. For HF-
cachexia vs each other group: **p<0.01. 
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Figure 3.2. Duration of exercise by NYHA Classification. Categorical characteristics 
compared with Fisher￿s exact test. For NYHA IV vs III and II: **p<0.01. 
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As discussed in chapter 2 we decided to use the STEEP (Standardised Exponential 
Exercise Protocol) protocol, which by employing one-minute stepwise increments in 
speed or gradient, is thought to be more appropriate in patients with significant 
limitation in exercise capacity. The smaller increments are proposed to make it less 
likely that subjects will stop early following a transition of workload, avoiding 
grouping of subjects￿ duration of exercise and elucidating a spread of exercise 
capacity. While we continued to observe some grouping around the 60 seconds 
increments there was a reasonable spread of exercise duration as illustrated in figure 
3.3.  
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Figure 3.3. Spread of exercise duration using the STEEP protocol. 
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Co-morbidity and drug therapy 
As expected in a study of ischaemic cardiomyopathy, heart failure patients were more 
likely to have had a previous myocardial infarction (table 3.3). While atrial 
fibrillation (AF) and type 2 diabetes mellitus were more prevalent in patients with 
heart failure, the between group differences were not significant.  
 
Mean serum creatinine was higher, and estimated glomerular filtration rate (eGFR) 
lower, in the HF-cachexia group than in the CAD and healthy control groups (table 
3.4). Although sodium, albumin and haemoglobin concentrations were lowest in the 
HF-cachexia group, the between group differences were not significant.  
 
Patient groups were on appropriate contemporary drug therapy (table 3.5). Although 
heart failure patients with cachexia were less likely to be receiving a beta-blocker, 
there was no significant difference in beta-blocker, angiotensin converting enzyme 
(ACE) inhibitor or angiotensin receptor blocker (ARB) therapy between the patient 
groups. As would be anticipated, there was less statin therapy in the IDCM group 
than in the patient groups with CAD.  
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  HF-cachexia 
(n=10)  
HF-no 
cachexia 
(n=20) 
CAD 
(n=10) 
 IDCM 
(n=7) 
Previous MI (%)  70  75  20
* 0
* 
Diabetes (%)  30  45  10  14.3 
Hypertension (%)  10  25  30  0 
Angiography (%)   60  65  80  0 
AF (%)  30  10  10  14.3 
 
Table 3.3. Co-morbidity. MI = myocardial infarction and AF = atrial fibrillation. 
Comparisons using Fisher￿s exact test. For HF-cachexia vs each other group: *p<0.05. 
 
 
  HF-
cachexia 
(n=10)  
HF-no 
cachexia 
(n=20) 
CAD 
(n=10) 
 IDCM 
(n=7) 
HC  
(n=9) 
Creatinine 
(µmol/l) 
127.5 (21.5)  129.1 (29.7)  96.4 (14.2)
 * 126.6 
(24.8) 
84.6 (8.2)
 * 
eGFR 
(ml/min/ 
1.73m
2) 
46.2 (6.4)  53.4 (13.8)  72 (10.3)
 **  54.7 (8.6)  74.7 (9.0)
 ** 
Sodium (Na
+) 
(mmol/l) 
138.7 (4.7)  141.0 (3.3)  142.1 (1.5)    -  141.3 (1.9) 
Albumin (g/l)  39.8 (5.0)  44.0 (3.2)  43.6 (2.4)  -  - 
Haemoglobin 
(g/dl) 
12.4 (2.0)  13.8 (1.5)  13.6 (0.8)  -  13.1 (1.0) 
 
Table 3.4. Baseline blood results.  eGFR = estimated glomerular filtration rate 
(Modification of Diet in Renal Disease 1). Differences between groups assessed by ANOVA 
or Kruskal-Wallis ANOVA. Post hoc analysis with Dunnett￿s or Dunn￿s multiple 
comparisons. For HF-cachexia vs each other group: *p<0.05, **p<0.01. 
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  HF-cachexia 
(n=10)  
HF-no 
cachexia 
(n=20) 
CAD 
(n=10) 
 IDCM 
(n=7) 
Beta-blocker (%)  40  75  70  85.7 
ACE inhibitor (%)  90  85  70  85.7 
ARB (%)  10  5  10  0 
Loop diuretics (%)   90  80  0
￿￿￿ 85.7 
Digoxin (%)  50  20  0
* 57.1 
Statin (%)  70  80  90  28.6 
 
Table 3.5. Drug therapy. ACE Inhibitor = angiotensin converting enzyme inhibitor; ARB 
= angiotensin receptor blocker. Comparisons using Fisher￿s exact test. For HF-cachexia vs 
each other group: *p<0.05, 
￿￿￿p<0.0001. 
 
Body morphology (figure 3.4) 
Mean BMI was significantly lower in the HF-cachexia group than in each of the other 
groups: HF-cachexia 20.0 (5.0) Kg.m
-2 compared to HF-no cachexia 29.2 (4.7) Kg.m
-
2, CAD 28.8 (3.7) Kg.m
-2, IDCM 30.5 (4.6) Kg.m
-2, and HC 29.6 (7.6) Kg.m
-2 
(p<0.01 for HF-cachexia compared to each other group).  
 
Mean percentage body fat was also significantly lower in the HF-cachexia group than 
in each of the other groups: HF-cachexia 15.5 (3.9) %
 compared to HF-no cachexia 
31.7 (6.1) %, CAD 28.5 (5.7) %, and HC 32.6 (10.9) % (p<0.05 for HF-cachexia 
compared to each other group).   
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Mean waist circumference was lowest in the HF-cachexia group, but this was only 
significant in comparison to HF-no cachexia group: HF-cachexia 836.2 (119.8) mm, 
HF-no cachexia 1021.8 (134.6) mm, CAD 977.2 (105.2) mm, and HC 957.8 (150.6) 
mm (p<0.01 for HF-cachexia compared to HF-no cachexia).  
 
Conversely, mean FFMI did not differ between the groups: HF-cachexia 18.0 (3.3) 
Kg.m
-2, HF-no cachexia 19.6 (2.1) Kg.m
-2, CAD 20.7 (2.4) Kg.m
-2, and HC 19.4 (2.7) 
Kg.m
-2. 
 
  85
 
Figure 3.4. Body composition. HF-cachexia, n=10; HF-no cachexia, n=20; CAD, n=10; 
HC, n=9. Differences between groups assessed by ANOVA or Kruskal-Wallis ANOVA. Post 
hoc analysis with Dunnett￿s or Dunn￿s multiple comparisons. For HF-cachexia vs each other 
group: *p<0.05, **p<0.01. 
 
Serum cytokines and C-reactive protein (CRP) (figure 3.5) 
Serum concentrations of TNF-α were highest in patients with IDCM, although not 
significantly higher than in patients with HF-cachexia: HF-cachexia 27.2 (21.8-132.8) 
pg/ml, HF-no cachexia 11.7 (2.6-27.3) pg/ml, CAD 25.6 (5.3-51.3) pg/ml, IDCM 
42.8 (12.7-85.8) pg/ml, and HC 12.7 (3.6-16.3) pg/ml (Biomarker concentrations 
given as median (range).  TNF-α levels were significantly higher in patients with HF-
cachexia than in patients with HF-no cachexia and controls (p<0.01 for both 
comparisons), but not significantly higher than in patients with CAD. 
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Figure 3.5. Circulating cytokines and C-reactive protein. HF-cachexia, n=10; HF-no 
cachexia, n=20; CAD, n=10; HC, n=9. Differences between groups assessed by ANOVA or 
Kruskal-Wallis ANOVA. Post hoc analysis with Dunnett￿s or Dunn￿s multiple comparisons. 
For HF-cachexia vs each other group: *p<0.05, **p<0.01. 
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Serum concentration of IL-6 was highest in patients with HF-cachexia, but this was 
only significant in comparison to the CAD group: HF-cachexia 12.2 (3.1-25.7) pg/ml, 
HF-no cachexia 8.2 (3.4-22.8) pg/ml, CAD 5.5 (2.6-10.4) pg/ml, IDCM 5.2 (3.9-12.7) 
pg/ml, and HC 6.6 (3.1-13.6) pg/ml (p<0.05 for HF-cachexia compared to CAD 
group).  
 
CRP concentration did not differ between the groups: HF-cachexia 3.8 (0.2-12.5) 
mg/l, HF-no cachexia 3.7 (0.2-28.6) mg/l, CAD 2.3 (0.3-18.4) mg/l, IDCM 2.0 (0.5-
6.0) mg/l, and HC 2.0 (0.5-3.7) mg/l.  
 
Skeletal muscle histology 
There was no microscopic evidence of muscle inflammation. Quantitative analysis of 
fibre type composition (percentage area of type I, IIA and IIB fibres), fibre thickness, 
and muscle area is awaited.  
 
Skeletal muscle cytokine gene expression 
There was no between group difference in relative expression of mRNA for TNF-α, 
IL-1β, IL-6 or IL-18 in skeletal muscle (table 3.6). 
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  HF-cachexia 
(n=7)  
HF-no cachexia
(n=14)  
CAD 
(n=5) 
HC 
(n=5) 
TNF-α 
(relative units) 
0.74 (0.70-0.79)  0.72 (0.69-0.81)  0.70 (0.70-0.72)  0.72 (0.70-0.75) 
IL-1β  
(relative units) 
0.84 (0.78-1.00)  0.81 (0.77-0.95)  0.83 (0.80-0.94)  0.84 (0.79-0.91) 
IL-6  
(relative units) 
0.96 (0.90-0.98)  0.90 (0.82-1.01)  0.93 (0.89-1.00)  0.96 (0.92-0.98) 
IL-18  
(relative units)  
1.20 (1.04-1.23)  1.12 (0.97-1.26)  1.17 (1.04-1.21)  1.24 (0.95-1.53) 
 
Table 3.6. Relative expression of mRNA for cytokines in skeletal muscle. Cytokine 
expression given as a ratio relative to β-actin expression. Biomarkers given as median 
(range). TNF-α = tumour necrosis factor- α; IL-1β = interleukin-1β; IL-6 = interleukin-6; IL-
18 = interleukin-18. Differences between groups assessed by ANOVA or Kruskal-Wallis 
ANOVA. For HF-cachexia vs each other group: p>0.05 for all comparisons. 
 
 
Skeletal muscle CDK inhibitor gene expression 
There was no between group difference in relative expression of mRNA for p21, p27 
or p57 in skeletal muscle (table 3.7). 
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  HF-cachexia 
(n=7)  
HF-no cachexia 
(n=14) 
CAD  
(n=5) 
HC 
(n=5) 
p21 (relative 
units) 
1.16 (1.13-1.32)  1.08 (0.98-1.33)  1.24 (1.06-1.30)  1.15 (1.10-1.20) 
p27 (relative 
units) 
1.20 (1.09-1.26)  1.21 (1.04-1.32)  1.20 (1.18-1.26)  1.24 (1.16-1.34) 
p57 (relative 
units) 
1.09 (1.03-1.15)  1.06 (1.04-1.10)  1.08 (0.90-1.11)  1.08 (0.94-1.12) 
 
Table 3.7. Relative expression of mRNA for CDK inhibitors in skeletal muscle. 
CDK inhibitor expression given as a ratio relative to β-actin expression. Biomarkers given as 
median (range). Differences between groups assessed by ANOVA or Kruskal-Wallis 
ANOVA. For HF-cachexia vs each other group: p>0.05 for all comparisons. 
 
 
Skeletal muscle cytokine and CDK inhibitor protein expression 
The lack of difference in gene expression was confirmed by finding no difference in 
TNF-α, IL-6 or p21 protein expression in a subgroup of subjects. 90
Discussion 
Using the arbitrary definition of cachexia as an unintentional weight loss of ≥ 7.5% 
body weight over ≥6 months we found that the reduction in body weight in cachectic 
heart failure patients is predominantly due to loss of fat with the relative preservation 
of fat free mass, contradicting prior hypotheses and assumptions about the nature of 
cardiac cachexia. We found that heart failure patients with cachexia had significantly 
lower BMI and percentage body fat than the other subject groups, but with a non-
significant reduction in fat free mass index.  
 
In addition to being unable to demonstrate evidence of muscle wasting in our patients 
with cardiac cachexia, and despite evidence of increased concentrations of cytokines 
in the blood, there was no local cytokine activation in skeletal muscle. There was an 
outlying TNF-α concentration in the HF-cachexia group, but even when excluded 
there remained a clear trend to higher levels in the cachectic patients. There was a 
spread of TNF-α concentration in the CAD group. A possible explanation for this 
would be the presence of patients with unstable coronary disease in the CAD group. 
Unstable CAD is known to be associated with increased systemic inflammation.  
 
While our finding of increased blood cytokines is very consistent with prior studies 
(Levine et al, 1990; McMurray et al, 1991; Anker et al, 1999), our muscle findings 
disagree with the only other study to quantify the expression of cytokines in skeletal 
muscle in heart failure (Gielen et al, 2003). Geilin et al reported increased relative 
expression of mRNA for TNF-α, IL-1β and IL-6 in skeletal muscle of similar 
numbers of patients with heart failure compared to healthy controls (Gielen et al,  91
2003). Importantly, their study population consisted of patients with predominantly 
idiopathic dilated cardiomyopathy (IDCM). One possible explanation for our 
discrepant findings is that patients with IDCM have tissue as well as blood cytokine 
activation compared to patients with ischaemic heart disease. Although the findings 
from previous studies comparing circulating cytokines in ischaemic and dilated 
cardiomyopathy have been conflicting, we found higher concentrations of circulating 
TNF-α in patients with IDCM than in those with ischaemic heart failure (Conraadsa 
et al, 2003; Munger et al, 1996; Tentolouris et al, 2004). Increased expression of 
TNF-α has also been reported in the myocardium of patients with IDCM (Satoh et al, 
2005). This raises the question of whether the skeletal muscle inflammation observed 
by Geilin et al is related to the process causing IDCM rather than arising as a 
consequence of heart failure per se.  
 
Another possible explanation could be differences in drug therapies with supposed 
anti-inflammatory effects. ACE inhibitor, ARB and beta-blocker therapy have been 
shown to be associated with reduced circulating cytokines or CRP (Gullestad et al, 
1999; Gurlek et al, 2001; Joynt et al, 2004). There was very high use of ACE 
inhibitor therapy in both the Geilin et al and our study (95% and 90%).  40% of heart 
failure patients in the Geilin et al study were treated with beta-blockers in comparison 
to 75% of our HF-no cachexia group and 40% in our HF-cachexia group. While this 
difference between our groups should be noted, observational evidence that beta-
blocker therapy is associated with reduced CRP in heart failure is not supported by 
the Metoprolol Controlled-Release Randomised Intervention Trial (MERIT-HF) 
substudy which reported no effect of beta-blocker therapy on TNF-α or IL-6  92
concentrations (Joynt et al, 2004; Gullestad et al, 2001). As expected in a study of 
ischaemic heart failure, a large proportion of our patients were on statin therapy (70% 
in the HF-cachexia and 80% in the HF-no cachexia groups). There is no information 
on statin use in the Geilin et al study, although we might anticipate that this would 
have been lower due to the predominance of patients with non-ischaemic heart 
failure.  Contrary to the possible anti-inflammatoy effect of statins it is important to 
note that they can also be associated with skeletal muscle myositis in a small 
proportion of patients.  
 
Of further importance are differences in drug therapies with metabolic effects. Recent 
studies have demonstrated that beta-blockers, ACE inhibitors and ARBs prevent 
lipolysis and weight loss (Lainscak et al, 2006; Anker et al, 2003; Cabassi et al, 
2006). Two small studies have suggested that beta-blocker therapy, by reducing 
catecholamine mediated lipolysis, may be associated with increased body fat and 
weight gain in heart failure, particularly in patients with cachexia (Hryniewicz et al, 
2003; Lainscak et al, 2006). Although there was no significant difference in drug 
therapy between our HF-cachexia and HF-no cachexia groups the observation that 
patients with cachexia were less likely to be receiving a beta-blocker may be of 
importance.    
 
Having found evidence of increased cytokines in the blood of our patients with 
cardiac cachexia, but no evidence of cytokine activation in skeletal muscle, this raises 
the question of where the circulating cytokines are coming from. Adipose tissue is 
known to produce and secrete TNF-α, and it has previously been suggested that  93
dysregulation of its production could be important in cachexia (Warne et al, 2003). 
Kern  et al reported increased adipose tissue TNF-α concentration in obesity, and 
found a positive relationship between TNF-α and both BMI and body fat. 
Interestingly, very obese subjects were found to have reduced adipose tissue TNF-α 
(Kern et al, 1995).  
 
In addition to finding no local cytokine activation, and contrary to our groups 
previous findings in patients with chronic obstructive pulmonary disease (COPD), 
there was no muscle tissue activation of cell cycle inhibitors in our heart failure 
patients with cachexia. As discussed previously, the definition of cachexia in COPD 
requires a reduction in FFMI in addition to BMI. This finding could be explained 
simply by the absence of muscle wasting in our HF-cachexia patients. 
 
In conclusion, weight loss in ischaemic heart failure predominantly involves the loss 
of adipose tissue with the relative preservation of muscle and bone. Despite the 
presence of increased circulating levels of inflammatory cytokines  we found no 
evidence of activation of skeletal muscle cytokines or cell cycle inhibitors in our 
cachectic heart failure patients.  94
 
 
 
 
CHAPTER 4 
 
ENERGY METABOLISM IN CARDIAC CACHEXIA  95
Introduction 
Having found that the reduction in body weight in our heart failure patients with 
cachexia was predominantly due to loss of fat mass, with the relative preservation of 
fat free mass, we were interested to assess substrate energy metabolism in our study 
population.  
 
A number of small studies have previously assessed changes in whole body substrate 
metabolism in heart failure. Increased levels of fat oxidation and free fatty acids, with 
decreased glucose oxidation and muscle glucose uptake, have consistently been 
reported. Increased protein turnover has also been reported, but in some studies this 
has only been present in patients with increased resting energy expenditure 
(Schneeweiss et al, 1987; Lommi et al, 1998; Norrelund et al, 2006; Toth et al, 2006). 
To the best of our knowledge there are no previous studies comparing substrate 
metabolism in heart failure patients with and without cachexia.  
 
We hypothesised that the reduction in body fat in our cachectic heart failure patients 
would be associated with a higher rate of fat oxidation than in our heart failure 
patients without cachexia.   96
Methods 
Subject groups 
As in the previous chapter, five groups of subjects were studied. Three were groups of 
patients with stable coronary artery disease (CAD): 1) HF-cachexia - patients with 
CAD, heart failure (HF), reduced left ventricular (LV) systolic function and cardiac 
cachexia, n=10; 2) HF-no cachexia - those with CAD, HF and reduced LV systolic 
function but no cachexia, n=20; and 3) CAD - those with CAD but no symptoms of 
HF and preserved LV systolic function, n=10. The other subject groups were 4) 
IDCM - patients with dilated cardiomyopathy, n=7; and 5) HC - healthy controls, 
n=9. 
 
Cardio-respiratory exercise testing and expired gas analysis 
All subjects had fasted overnight and performed a symptom limited cardio-respiratory 
treadmill exercise test using the STEEP (Standardised Exponential Exercise Protocol) 
protocol (table 2.1) (Northridge et al, 1990). Continuous 12-lead ECG monitoring and 
heart rate and blood pressure response were recorded. Exhaled air was analysed to 
determine metabolic gas exchange with a metabolic cart. Oxygen uptake (VO2) and 
carbon dioxide production (VCO2) were determined on-line with breath-by-breath 
analysis. Resting breath analysis was performed prior to exercise until a steady state 
was achieved. The peak VO2 was averaged over the last 30 seconds of exercise. The 
respiratory exchange ratio (RER) was determined as the ratio of VCO2/VO2.   Rate of 
fat and carbohydrate oxidation was calculated by indirect calorimetry using the 
derived equations of Frayn (Frayn, 1983). 
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Derived equations for the calculation of substrate oxidation 
When glucose is oxidised according to the equation: 
Glucose (C6H12O6) + 6 O2  →  6 H2O + 6 CO2 
6 mol of O2 are consumed and 6 mol of CO2 are produced for each mole (180 g) of 
glucose oxidised, and the respiratory quotient (RQ = VCO2/VO2) is thus 1.00 (table 
4.1). 
 
When a typical fat (PSOG, palmitoyl-stearoyl-oleoylglycerol) is oxidised according 
to the equation: 
PSOG (C55H104O6) + 78 O2  →  55 CO2 + 52 H2O 
78 mol of O2 are consumed and 55 mol of CO2 produced for each mole (861 g) of fat 
oxidised. 
 
Fuel O2 l/g fuel  CO2 l/g fuel 
Glucose 0.746  0.746 
Fat 2.03  1.43 
Protein   0.966  0.782 
 6.04*    4.89* 
 
Table 4.1 Volumes of O2 consumed and CO2 produced in oxidation of various 
fuels. Reproduced from Frayn, 1983. 1 mol of gas occupies 22.4 liters. * Volumes expressed 
per g urinary nitrogen. 
 
The amount of protein oxidised may be estimated from urinary nitrogen excretion. 
Most urinary nitrogen (>80%) is in the form of urea with 1 g of urinary nitrogen 
arising from approximately 6.25 g of protein (Magnus-Levy, 1907).  
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Therefore, in a subject oxidising c grams of carbohydrate (as glucose) and f grams of 
fat per minute, and excreting n grams of urinary nitrogen per minute, the total O2 
consumption and total CO2 production, using values from table 4.1, are thus given by: 
VO2 (l/min) = 0.746 c + 2.03 f + 6.04 n 
VC02 (l/min) = 0.746 c + 1.43 f + 4.89 n 
 
These equations can be solved for the unknown variables c and f (gaseous exchange 
and urinary nitrogen excretion being measurable) as follows: 
c = 4.55 VCO2 - 3.21 VO2 - 2.87 n 
f = 1.67 VO2 - 1.67 VCO2 - 1.92 n 
 
Making the assumption that there is neglible protein oxidation the equations become: 
CHO oxidation (g/min) = 4.55 VCO2  - 3.21 VO2 (l/min) 
Fat oxidation (g/min) = 1.67 VO2 - 1.67 VCO2 (l/min) 
 
This standard technique for measuring substrate metabolism in vivo makes a number 
of assumptions and thus has limitations. Notably, calculated estimates are net 
substrate oxidation rates (ie. calculated carbohydrate oxidation represents the 
oxidation of either endogenous glycogen or exogenously administered carbohydrate). 
In addition, it assumes that there is negligible protein oxidation. While this 
assumption may have been anticipated to be a significant limitation to this technique 
in heart failure patients, our finding of preserved fat free mass in our non-cachectic 
and cachectic patients suggested this is a reasonable assumption to make. It would be 
ideal to have measured urinary nitrogen. If this assumption is incorrect and our  99
patients had increased protein turnover, the equations would overestimate rates of 
oxidation of both substrates, with the error being greater for rate of carbohydrate 
metabolism.  100
Results 
Expired gas analysis and calculated rates of substrate oxidation 
The HF-cachexia group had the highest rate of fat oxidation and the lowest rate of 
carbohydrate oxidation, although with the small subject numbers the differences were 
not statistically significant (table 4.1)(figure 4.1). 
 
  HF-cachexia 
(n=10) 
HF-no cachexia 
(n=20) 
CAD 
(n=10) 
HC 
(n=9)  
Resting VO2  
(mL.min
-1) 
297.6 (96.7)  344.6 (106.6)  301.4 (50.8)  283.7 (49.2) 
Resting CO2 
(mL.min
-1) 
237.9 (40.3)  296.4 (94.2)  290.9 (79.4)  248.9 (53.8) 
Respiratory 
exchange ratio 
(RER) 
0.77 (0.1)  0.85 (0.1)  0.82 (0.1)  0.88 (0.1) 
Fat oxidation 
(mg/min) 
138.6 (112)  91.3 (46.7)  96.0 (45.8)  61.0 (18.4) 
CHO oxidation 
(mg/min) 
45.6 (167.2)   233.1 (143.2)  143.8 (127.7)  215.9 (44.6) 
 
Table 4.2. Expired gas analysis and rates of substrate metabolism. Differences 
between groups assessed by ANOVA. For HF-cachexia vs each other group: p>0.05 for all 
comparisons.  101
 
Figure 4.1. Rates of fat oxidation by subject group.  Differences between groups 
assessed by ANOVA. For HF-cachexia vs each other group: p>0.05 for all comparisons. 
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Discussion 
We found that our cachectic heart failure patients had altered substrate metabolism, 
with increased rates of fat oxidation and decreased rates of carbohydrate oxidation, 
compared to heart failure patients without cachexia (although with our small subject 
numbers the differences did not achieve statistical significant). This raises the 
question of what is mediating increased fat metabolism and loss of fat mass in cardiac 
cachexia. 
 
A key role for the sympathetic nervous system with catecholamine mediated lipolysis 
has been proposed for many years. Catecholamines, through binding to β-receptors on 
the surface of adipocytes, and via a cyclic adenosine monophosphate (cAMP) 
dependent pathway, result in the phosphorylation, and hence activation, of lipase. 
Studies comparing circulating noradrenaline levels have tended to find higher 
concentrations in cachectic than non-cachectic heart failure patients (Nagaya et al, 
2001; Hryniewicz et al, 2003). Beta-blocker therapy, while not associated with any 
significant change in catecholamine levels in non-cachectic heart failure patients, has 
been associated with a greater reduction in noradrenaline concentration in cachectic 
compared to non-cachectic heart failure patients (Podbregar et al, 2002; Hryniewicz 
et al, 2003). Two small studies in heart failure patients have suggested that beta-
blockers prevent weight loss, and may be associated with increased body fat and 
weight gain, particularly in patients with cachexia (Hryniewicz et al, 2003; Lainscak 
et al, 2006). This is supported by a recent in vivo study demonstrating that beta-
blockers reduce lipolysis in rats (Cabassi et al, 2006). While this all supports a 
significant contribution of the sympathetic nervous system to increased rates of fat  103
metabolism and the development of cachexia, there are clearly other important 
mediators involved.   
 
The presence of higher TNF-α concentrations in patients with cachexia has lead to the 
suggestion that circulating TNF-α may play a role in tissue wasting. (Levine et al, 
1990; McMurray et al, 1991; Dutka et al, 1993; Anker et al, 1997). Argiles et al 
proposed that elevated circulating TNF-α is responsible for the metabolic alteration in 
adipose tissue in cachexia (Argiles et al, 1997). TNF-α is also produced by adipose 
tissue itself with the alternative suggestion that, through the autocrine and paracrine 
actions of promoting lipolysis and inhibiting lipogenesis, that adipose tissue derived 
TNF-α, as opposed to circulating TNF-α, mediates the depletion of adipose tissue 
mass in cachexia (Kern et al, 1995; Warne et al, 2003). 
  
Adipose tissue is now known, in addition to cytokines, to produce hormones 
important in the regulation of energy metabolism. There has been particular interest 
in the more recently discovered leptin and adiponectin. Adiponectin, in particular, is 
known to have an inverse relationship to body mass index and body fat, and to 
possibly be regulated by TNF-α. (Maeda et al, 1996; Chandran et al, 2003; Meier et 
al,  2004; Yamauchi et al, 2002; Bruun et al, 2003; Wang et al, 2006; Degawa-
Yamauchi et al, 2005; Carey et al, 2006). The observation that adiponectin induces 
weight loss in experimental animal models raises the possibility that it may play an 
important role in the pathogenesis of cachexia (Fruebis et al, 2001; Masaki et al, 
2003). 
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The presence and significance of increased circulating levels of natriuretic peptides 
has been well described in patients with heart failure (Yu et al, 1999; Troughton et al, 
2000; Selvais et al, 2000; Berger et al, 2002, Lee et al, 2002). More recently it has 
been suggested that natriuretic peptides may also have lipolytic and lipid-mobilising 
actions (Sengenes et al, 2000). These actions of natriuretic peptides appear to be 
independent of catecholamines and mediated by specific adipocyte membrane 
receptors, which operate via a cGMP-dependent pathway. Although higher levels of 
BNP have been described in patients with more advanced heart failure no relationship 
with cachexia has as yet been investigated. 
 
In conclusion, we found that our cachectic heart failure patients had reduced body fat 
and increased rates of fat metabolism. We propose that adiponectin and natriuretic 
peptides may be important mediators of this process, possibly under the regulation of 
the inflammatory cytokines.  105
 
 
 
 
CHAPTER 5 
 
INCREASE IN SERUM ADIPONECTIN CONCENTRATION IN 
PATIENTS WITH HEART FAILURE AND CACHEXIA: 
RELATIONSHIP WITH LEPTIN, OTHER CYTOKINES AND  
B-TYPE NATRIURETIC PEPTIDE 
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Introduction 
Having found that our cachectic heart failure patients had reduced body fat and 
increased fat metabolism we proceeded to investigate possible mediators of this 
altered energy metabolism and wasting process. 
 
As discussed briefly in the preceding chapter, there has been previous interest in the 
hormones that regulate appetite and metabolism in patients with heart failure. In 
particular, leptin production may be inappropriately low in cachectic heart failure 
patients (Murdoch et al, 1999; Schulze et al, 2003). More recently adiponectin, an 
adipose tissue-specific peptide, has been thought to play an important role in the 
regulation of energy metabolism having been observed to inversely correlate with 
body mass index and body fat (Maeda et al, 1996; Chandran et al, 2003; Meier et al, 
2004). Obesity is associated with reduced adiponectin levels whereas these are 
increased in anorexia nervosa (Iwahashi et al, 2003; Pannacciulli et al, 2003; 
Delporte et al, 2003). In experimental animals, including genetically modified ones, 
administration of adiponectin reduces weight gain or leads to weight loss (depending 
on the model), possibly by increasing energy expenditure (Fruebis et al, 2001; 
Yamauchi et al, 2002; Masaki et al, 2003). Plasma adiponectin concentrations have 
recently been reported to be increased in patients with heart failure (Kistorp et al, 
2005; George et al, 2006).  
 
As discussed previously, a lipolytic and potential lipid-mobilising effect of natriuretic 
peptides has been described (Sengenes et al, 2000). This is supported by the 
observation that B-type natriuretic peptide (BNP) correlates inversely with BMI in  107
heart failure patients (Horwich et al, 2006). The actions of BNP appear to be 
mediated by specific adipocyte membrane receptors, which operate  via a cGMP-
dependent pathway, and may indirectly stimulate adiponectin production (Sengenes et 
al,  2000). Interestingly, N-terminal pro-BNP (NT-proBNP) has previously been 
observed to have a positive relationship with plasma adiponectin levels in patients 
with heart failure (Kistorp et al, 2005).  
 
We hypothesised that increased fat metabolism in cachectic heart failure patients is 
mediated by adiponectin, possibly under the regulation of TNF-α an d  B N P .   W e 
therefore measured serum adiponectin concentrations in our cachectic and non-
cachectic heart failure patients, and analysed the relationship of adiponectin with 
body composition, leptin, inflammatory cytokines, BNP and rate of fat oxidation.  108
Methods 
Subject groups 
We studied four of our subjects groups. Three were groups of patients with stable 
coronary artery disease (CAD): 1) HF-cachexia - patients with CAD, heart failure 
(HF), reduced left ventricular (LV) systolic function and cardiac cachexia, n=10; 2) 
HF-no cachexia - those with CAD, HF and reduced LV systolic function but no 
cachexia, n=20; and 3) CAD - those with CAD but no symptoms of HF and preserved 
LV systolic function, n=10. The fourth group were 4) HC - healthy controls, n=7.  
 
It was important that only patients with CAD were studied as there may be a 
difference in adiponectin  levels between individuals with and without CAD. Two 
healthy control subjects  were excluded for age-matching to the patient groups. 
Subject groups characteristics and body composition data is therefore revised with 
this alteration.  
 
Subject characterisation 
Subject characterisation by NYHA classification, LVEF, peak VO2, body 
morphology and composition, co-morbidity and drug therapy has been described in 
detail earlier.  
 
Rate of fat oxidation was calculated as described in detail in chapter 4. 
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Blood sample collection and analysis 
All subjects had fasting blood samples taken between 9 and 10 am. Blood samples 
were placed on ice, allowed to clot for 20 minutes and then centrifuged at 3000 rpm 
for 15 minutes at 4 °C. The serum or plasma was aliquoted and stored at ￿80 °C until 
analysis. Serum adiponectin, leptin, tumour necrosis factor α (TNF-α) and 
interleukin-6 (IL-6) were measured in triplicate using commercially available 
enzyme-linked immunosorbent assay kits (Quantikines, R&D systems). Cholesterol, 
triglycerides, VLDL cholesterol, LDL cholesterol, HDL cholesterol and high 
sensitivity CRP concentrations were also measure using a Hitachi 917 analyser 
(Roche kits). Fasting glucose and insulin were measured and the homeostasis model 
assessment (HOMA-IR) index calculated to estimate insulin resistance (Matthews et 
al, 1985). Blood for the measurement of plasma B-type natriuretic peptide (BNP) was 
added to a chilled tube containing ethylenediaminetetraacetic acid (EDTA). Plasma 
BNP was measured using the Shionoria immunoradiometric kit (Schering CIS, West 
Sussex, England). 
 
Statistical analysis 
Results are expressed as mean (SD) for baseline characteristics and median (range) 
for biomarkers. Two-sided tests of significance were used. Normality testing and 
Bartlett￿s test for homogeneity of variance were performed and differences between 
groups assessed by one-way analysis of variance (ANOVA) or Kruskal-Wallis non-
parametric ANOVA. Where differences were identified, a Dunnett￿s or Dunn￿s 
multiple comparison post hoc test was performed. Fisher￿s exact test was used to 
compare categorical characteristics. The data was logarithmically transformed for  110
linear regression analysis and a Run￿s test used for departure from linearity. The 
relationship of adiponectin to other biomarkers was further assessed by multiple 
linear regression analysis adjusting for age, BMI, eGFR and insulin resistance. 
Statistical significance was taken at the 5% level.  111
Results 
Subject characteristics 
Mean age was higher in the heart failure patients with cachexia than in the other 
groups, although this difference was not significant. Mean LVEF, peak VO2 and 
eGFR were all lower in patients with heart failure than in the control groups (table 5.1 
and 5.2). Patients with cachectic heart failure had worse NYHA functional class and a 
lower peak VO2 than non-cachectic heart failure patients. Drug therapy for each of the 
patients groups was previously outlined in table 3.4. 
 
 
  HF-cachexia 
(n=10) 
HF-no 
cachexia 
(n=20) 
CAD  
(n=10) 
 HC 
(n=7) 
Mean age (years)   72.7  67.6  64.4  63.0 
Gender (M/F)  8/2  18/2  9/1  4/3 
NHYA (I/II/III)  0/7/3  12/8/0  -  - 
LVEF (%)  27.1 (11.9)  35.4 (9.7)  73.0 (6.4)**  68.4 (6.1)** 
Peak VO2 
(ml.Kg
-1.min
-1) 
9.8 (2.3)  13.6 (3.9)*  21.2 (2.0)**  26.4 (5.5)** 
 
Table 5.1. Subject characteristics. LVEF measured using dual region of interest (normal 
≥55%). Differences between groups assessed by ANOVA or Kruskal-Wallis ANOVA. Post 
hoc analysis with Dunnett￿s or Dunn￿s multiple comparisons. Categorical characteristics 
compared using Fisher￿s exact test. For HF-cachexia vs each other group: *p<0.05, **p<0.01. 
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  HF-cachexia 
(n=10) 
HF-no 
cachexia 
(n=20)  
CAD  
(n=10) 
HC  
(n=7) 
Previous MI (%)  70  75  20*  - 
Diabetes (%)  30  45  10  - 
Hypertension (%)   10  25  30  - 
Mean creatinine 
(µmol/l) 
127.5 (21.5)  129.1 (29.7)  96.4 (14.2)*  85.1 (8.6)* 
eGFR 
(ml/min/1.73m
2) 
46.2 (6.4)  53.4 (13.8)  72 (10.3)**  75.9 (8.4)** 
 
Table 5.2. Co-morbidity. eGFR = estimated glomerular filtration rate (Modification of 
Diet  in Renal Disease 1).  Categorical variables compared using Fisher￿s exact test. 
Differences between groups for continuous variables assessed by ANOVA. Post hoc analysis 
with Dunnett￿s multiple comparisons. For HF-cachexia vs each other group: *p<0.05, 
**p<0.01. 
 
 
Body composition analysis 
Mean body mass index (BMI) and percentage body fat were substantially lower in the 
heart failure patients with cachexia than in the other groups (table 5.3). HF-cachexia 
patients had the lowest waist circumference, but this was only significantly lower 
than in the HF-no cachexia group. There was no significant difference in body 
composition between the HF-no cachexia, CAD and healthy control groups. 
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  HF-cachexia 
(n=10)  
HF-no cachexia 
(n=20) 
CAD  
(n=10) 
HC  
(n=7) 
Body Mass 
Index (Kg m
-2) 
20.0 (5.0)  29.2 (4.7)
** 28.8  (3.7)
** 27.0  (4.6)
** 
Body fat  
(%) 
15.5 (3.9)  31.7 (6.1)
** 28.5  (5.7)
** 29.2  (9.8)
** 
Waist 
circumference 
(mm) 
836.2 (119.8)  1021.8 (134.6)
**  977.2 (105.2)  923 (138) 
 
Table 5.3. Body composition.  Differences between groups assessed by ANOVA or 
Kruskal-Wallis ANOVA. Post hoc analysis with Dunnett￿s or Dunn￿s multiple comparisons. 
For HF-cachexia vs each other group: *p<0.05, **p<0.01. 
 
Serum adiponectin concentration 
The HF-cachexia group had a significantly higher median serum adiponectin 
concentration than those in each of the other groups (table 5.4) (figure 5.1). This 
remained true after adiponectin concentration was adjusted for fat mass or BMI. 
Because adiponectin shows sexual dimorphism (with higher serum concentrations in 
females), we also repeated this analysis in male subjects only. Adiponectin levels 
remained significantly higher in HF patients with cachexia: 22.5 (10.2-37.2) µg/ml 
compared to 7.1 (0.5-16.6) µg/ml in the HF no-cachexia group and 7.0 (0.4-10.7) 
µg/ml in the CAD controls and 9.8 (2.5-16.8) µg/ml in the healthy controls. 
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 HF-cachexia 
(n=10) 
HF-no 
cachexia 
(n=20) 
CAD  
(n=10) 
HC  
(n=7) 
Adiponectin 
(￿g/ml) 
23.8 (10.2-37.2) 8.1 (0.5-16.6)
*   7.1 (0.4-13.5)
* 8.7  (2.5-16.8)
* 
Adiponectin 
adjusted for body 
fat (￿g/ml/Kg) 
2.2 (0.7-8.4)  0.3 (0.02-0.9)
* 0.3  (0.08-0.9)
* 0.4  (0.06-1.3) 
Adiponectin 
adjusted for BMI 
(￿g/ml/Kgm
-2) 
1.1 (0.4-3.3)  0.2 (0.02-0.6)
* 0.2  (0.01-0.5)
* 0.3  (0.07-0.8)
* 
 
Table 5.4. Serum adiponectin concentration. Results are expressed as median (range). 
Differences between groups assessed by ANOVA with post hoc analysis with Dunnett￿s 
multiple comparisons. For HF-cachexia vs each other group: *p<0.05. 
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Figure 5.1. Serum adiponectin concentrations in subject groups.  
**p<0.05 for cachexia vs each other group 
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Serum leptin concentration 
Patients in the HF-cachexia group had the lowest median serum leptin concentration, 
although there was no statistically significant difference from the other groups, with 
the exception of the CAD control group (table 5.5). This difference in leptin was no 
longer significant after adjusting for fat mass or BMI. 
 
 HF-cachexia 
(n=10) 
HF-no cachexia 
(n=20) 
CAD  
(n=10) 
HC  
(n=7) 
Leptin  
(ng/ml) 
9.5 (2.1-14.0)  12.6 (3.4-55.4)  20.8 (12.4-26.3)
** 11.1  (1.5-18.4) 
Leptin adjusted 
for body fat 
(ng/ml/Kg) 
1.0 (0.2-2.8)  0.5 (0.2-1.7)  0.8 (0.7-1.3)  0.4 (0.1-0.8) 
Leptin adjusted 
for BMI 
(ng/ml/Kgm
-2). 
0.6 (0.1-0.8)  0.4 (0.1-1.6)  0.7 (0.5-0.9)  0.4 (0.1-0.7) 
 
Table 5.5. Serum leptin concentration.  Results are expressed as median (range). 
Differences between groups assessed by ANOVA with post hoc analysis with Dunnett￿s 
multiple comparisons. For HF-cachexia vs each other group: **p<0.01. 
 
 
Concentrations of other serum cytokines  
Serum TNF-α concentration was significantly higher in the HF patients with cachexia 
than in the HF patients without cachexia and the healthy controls: HF-cachexia 27.2 
(21.8-132.8) pg/ml, HF-no cachexia 11.7 (2.6-27.3) pg/ml, CAD 25.6 (5.3-51.3) 
pg/ml, and HC 10.8 (3.6-16.3) pg/ml (p<0.01 for HF-cachexia compared to HF-no 
cachexia and HC groups). Although TNF-α concentration was higher in HF-cachexia 
group than in the CAD group, the difference was not statistically significant (figure  116
5.2). Although IL-6 concentration was higher in HF-cachexia group than in all other 
groups this was only significant on comparison to the CAD group (figure 5.2): HF-
cachexia 12.2 (3.1-25.7) pg/ml, HF-no cachexia 8.2 (3.4-22.8) pg/ml, CAD 5.5 (2.6-
10.4) pg/ml, and HC 5.4 (3.1-13.6) pg/ml (p<0.05 for HF-cachexia compared to CAD 
group). 
 
C-reactive protein (CRP) 
There was no significant difference in CRP concentration between the groups (figure 
5.2): HF-cachexia 3.8 (0.2-12.5) mg/l, HF-no cachexia 3.7 (0.2-28.6) mg/l, CAD 2.3 
(0.3-18.4) mg/l, and HC 1.6 (0.5-3.7) mg/l. 
 
B-type natriuretic peptide (BNP) 
Patients in the HF-cachexia group had higher median plasma BNP concentration than 
the HF-no cachexia group, although this difference was not statistically significant: 
HF-cachexia 484 (79-1609.5) pg/ml, HF-no cachexia 151 (22.5-557) pg/ml, CAD 
58.5 (3.0-173.7) pg/ml, and HC 22.5 (5.5-72.0) pg/ml. BNP concentrations were 
significantly higher in the HF-cachexia group than in the CAD and healthy control 
groups (p<0.01 for both comparisons) (figure 5.2). 
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Figure 5.2. Cytokines, B-type natriuretic peptide and C-reactive protein.  HF-
cachexia, n=10; HF-no cachexia, n=20; CAD, n=10; HC, n=7. Differences between groups 
assessed by ANOVA or Kruskal-Wallis ANOVA. Post hoc analysis with Dunnett￿s or 
Dunn￿s multiple comparisons. For HF-cachexia vs each other group: *p<0.05; **p<0.01. 
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Lipid profile 
There was no significant difference in the lipid profile of patients with HF and 
cachexia than the other patient groups (table 5.6). 
 
 HF-cachexia 
(n=10) 
HF-no 
cachexia 
(n=20) 
CAD 
(n=10) 
HC 
(n=7) 
Cholesterol 
(mmol/l) 
3.4 (2.2-5.5)  3.8 (2.6-5.4)  3.7 (3.1-5.1)  4.5 (3.2-6.4) 
Triglyceride 
(mmol/l) 
1.2 (0.8-4.9)  1.8 (0.9-5.0)  1.2 (0.7-2.0)  0.7 (0.6-1.4) 
VLDL-Cholesterol 
(mmol/l) 
0.5 (0.4-2.3)  0.8 (0.4-2.3)  0.5 (0.3-0.9)  0.3 (0.3-0.6) 
LDL-Cholesterol 
(mmol/l) 
1.4 (0.9-3.3)  2.1 (0.9-3.6)  2.0 (1.2-3.1)  2.6 (1.6-4.2) 
HDL-Cholesterol 
(mmol/l) 
0.8 (0.5-1.6)  0.8 (0.6-1.5)  1.1 (0.9-1.6)  1.3 (1.3-2.2) 
 
Table 5.6. Lipid profile. Results expressed as median (range). Differences between groups 
assessed by ANOVA or Kruskal-Wallis ANOVA. For HF-cachexia vs each other group: 
p>0.05 for all comparisons. 
 
 
Insulin resistance 
The median HOMA-IR index was 1.3 (0.5-33.1) in the HF-cachexia group, 5.9 (0.7-
24.8) in the HF-no cachexia group, 2.2 (0.7-7.3) in the CAD control group, and 1.5 
(0.7-3.7) in the healthy control group. There was no statistically significantly 
difference between the groups.  
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Rate of fat oxidation 
Rates of fat oxidation in each subject group are given in table 4.1 and illustrated in 
figure 4.2. 
 
Correlations  
In all patients studied (excluding healthy controls), BMI, percentage body fat, and 
waist circumference negatively correlated with adiponectin (r = -0.47, r = -0.47, and r 
= -0.44, respectively; p<0.01 for all relationships) (figure 5.3), and positively 
correlated with leptin concentration (r = 0.56, r = 0.52, and r = 0.52, respectively; 
p≤0.003 for all relationships).  120
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Figure 5.3. Relationship between serum adiponectin and body composition. 
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Body Mass Index (Kg.m-2) 
Percentage Body Fat (%)
Waist Circumference (mm)
r = -0.47, p<0.01 
r = -0.47, p<0.01 
r = -0.44, p<0.01  121
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Figure 5.4. Relationship between serum adiponectin, plasma BNP, and 
inflammatory cytokines. 
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Figure 5.5. Relationship between plasma BNP and body composition. 
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BNP positively correlated with adiponectin (r = 0.55, p = 0.0004) (figure 5.4) and 
negatively correlated with leptin (r = -0.36, p = 0.0363). There was an inverse 
correlation of BNP with BMI (r = -0.37, p = 0.0225) and percentage body fat (r = -
0.45, p = 0.006) (figure 5.5).  
 
There was an inverse relationship between adiponectin and insulin resistance (r = -
0.43, p = 0.0077).  
 
Adiponectin positively correlated with IL-6 (r = 0.34, p = 0.0325) while no 
relationship was observed with TNF-α (r = 0.27, p = 0.0928; Runs test p <0.05 with 
significant departure from linearity) (figure 5.4). 
 
Multiple linear regression analysis, using a model adjusting for age, BMI, eGFR and 
insulin resistance, demonstrated a positive relationship between adiponectin and BNP 
(r = 0.57, p = 0.0017) and TNF-α (r = 0.41, p = 0.0313). 
 
Rate of fat oxidation positively correlated with adiponectin (r = 0.57, p = 0.0018) but 
there was no relationship with BNP (r = 0.15, p = 0.4288) (figure 5.6).  
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Figure 5.6. Relationship between rate of fat oxidation, serum adiponectin and  
plasma BNP.
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r = 0.4585, p = 0.0162 
r = 0.15, p = 0.4288  125
Discussion 
We found that our cachectic heart failure patients, with reduced body fat and 
increased fat metabolism, had markedly elevated serum adiponectin concentrations 
compared to heart failure patients without cachexia.  
 
This is also to our knowledge the first study to report higher plasma concentrations of 
BNP in heart failure patients with cachexia (although with our small subject numbers 
this did not achieve statistical significance).  
 
Furthermore, we observed a positive relationship between adiponectin and BNP. Both 
negatively correlated with BMI and percentage body fat, and positively correlated 
with serum TNF-α concentration. While rate of fat oxidation positively correlated 
with adiponectin concentration, there was no relationship observed with BNP. 
 
At the very least, these findings suggest preservation of the supposed physiological, 
inverse, relationship between adiponectin and fat mass in cachexia (Chandran et al, 
2003; Meier et al, 2004).  More interestingly, our findings raise the possibility that 
adiponectin, possibly under the influence of TNF-α and BNP, contributes to increased 
fat metabolism, loss of fat mass and the development of cachexia in heart failure.  
 
Adiponectin levels have been inversely correlated with body mass and fat in the 
disordered metabolic states of obesity and anorexia nervosa. Adiponectin 
concentrations are decreased in obesity, while weight loss in obese subjects, induced 
by either dieting or gastric surgery, is associated with an increase in adiponectin  126
concentrations (Chandran et al, 2003; Meier et al, 2004; Holdstock et al, 2003). 
Contrary to this however are recent studies in non-obese, healthy volunteers showing 
weight loss to be associated with no change or a fall in plasma adiponectin 
concentrations (Wolfe et al, 2004; Mousavinasab et al, 2005).  Thus, the relationship 
between change in weight and adiponectin may not be the same in healthy and obese 
individuals. From our observations, it appears that the relationship of adiponectin to 
weight loss in cardiac cachexia is also different to that in healthy subjects.  
 
In fact the directional change in serum adiponectin concentrations in cardiac cachexia 
appears similar to that in patients with anorexia nervosa. Importantly, this eating 
disorder involves starvation, which is not a feature of cachexia, and neuropsychiatric 
abnormalities, which may alter endocrine function.  Furthermore, the increases in 
adiponectin reported in anorexia nervosa have been much less marked than we found 
in cardiac cachexia (Iwahashi et al, 2003; Pannacciulli et al, 2003; Delporte et al 
2003).
   
 
Obviously, a more direct way of establishing a ￿cause and effect￿ relationship 
between increased adiponectin and reduced weight would be to examine change in 
weight following administration of the peptide.  This has not been done in humans.  
However, studies conducted in experimental animals have shown a consistent effect 
of adiponectin to either prevent weight gain or induce weight loss (Fruebis et al, 
2001; Yamauchi et al, 2002; Masaki et al, 2003). 
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What are the possible mechanisms for the increased serum adiponectin concentrations 
in patients with cachectic heart failure?  The factors controlling adiponectin secretion 
are still poorly understood and controversial. It is striking that our cachectic patients 
had much higher levels despite a greatly reduced ￿endocrine￿ mass (i.e. fat tissue).   
 
TNF-α has been suggested to increase adiponectin secretion, although the literature is 
conflicting (Bruun et al, 2003; Wang et al, 2006; Degawa-Yamauchi et al, 2005; 
Carey et al, 2006).
  We found elevated serum TNF-α levels in our cachectic heart 
failure patients, as shown previously, and a positive relationship with adiponectin 
concentration (Anker et al, 1997; McMurray et al, 1991; Sengenes et al, 2000).  
These findings could also be interpreted as being consistent with the proposed anti-
inflammatory role of adiponectin. 
 
We also found increased BNP levels in our cachectic heart failure patients, and a 
positive relationship with adiponectin concentration, raising the possibility that 
natriuretic peptides might promote adiponectin secretion. As discussed earlier, BNP 
has lipolytic and potential lipid-mobilising effects, and is thought to indirectly 
stimulate adiponectin production, acting via adipocyte membrane receptors and a 
cGMP-dependent pathway (Sengenes et al, 2000). Our findings are consistent with 
Kistorp et al who found a positive relationship (albeit of lesser magnitude than seen 
in the present study) between plasma adiponectin levels and NT-proBNP 
concentration (Kistorp et al, 2005). BNP has previously been demonstrated to 
correlate inversely with BMI (Horwich et al, 2006). In addition to observing a similar  128
inverse relationship of BNP with BMI in our study, we also found an inverse 
relationship between BNP and percentage body fat. 
 
Reduced renal clearance, rather than increased secretion, might also account for our 
findings in cachectic heart failure patients, since adiponectin is cleared from the 
circulation by the kidneys (Chandran et al, 2003; Meier et al, 2004).  While many of 
our patients had reduced renal function, as evidenced by a reduced glomerular 
filtration rate, there was no marked difference in renal function between cachectic and 
non-cachectic patients. Thus, renal dysfunction is unlikely to explain the higher 
adiponectin concentrations in the cachectic heart failure patients. 
 
Type 2 diabetes is associated with reduced plasma adiponectin concentration, with the 
reduction in adiponectin closely related to the degree of insulin resistance and 
hyperinsulinaemia (Hotta et al, 2000; Weyer et al, 2001). It was therefore in some 
ways surprising to find that adiponectin was increased in our patients as heart failure 
is known to be a state of insulin resistance (Opie et al, 2004). 
 
Although not achieving statistical significance with our small subject numbers, as 
previously described, CRP concentration was highest in patients with heart failure, 
and elevated in patients with CAD in comparison to healthy subjects (Yin et al, 2004; 
Chirinos et al, 2003; Rosenson et al, 2004; Arroyo-Espliguero et al, 2004). 
 
The lipid profiles were strikingly similar in the patient groups, achieving currently 
recommended targets for CAD, with high levels of statin use. With heart failure  129
patients excluded from the large, randomised, clinical trials, and with the recent 
observation that reduced lipid levels may be associated with an adverse outcome in 
chronic heart failure, the efficacy and safety of statin therapy in heart failure patients 
is currently being investigated by the CORONA study (Rauchhaus et al, 2003; 
Kjekshus  et al, 2005; Scandinavian Simvastatin Survival Study Group, 1994; 
Longterm Intervention with Pravastatin in Ischaemic Disease Study Group, 1998; 
Heart Protection Collaborative Group, 2002).  
 
In conclusion, our cachectic heart failure patients had significantly increased serum 
concentrations of adiponectin. The observed relationships with BMI, percentage body 
fat, rate of fat metabolism, serum TNF-α, and plasma BNP concentrations suggests 
that adiponectin may be a key mediator of the cachectic process, possibly under the 
influence of TNF-α and BNP.   130
 
 
 
 
 
CHAPTER 6 
 
RELATIONSHIP BETWEEN PLASMA ADIPONECTIN 
CONCENTRATION AND RATE OF FAT METABOLISM  131
Introduction 
Having found markedly elevated adiponectin levels, an increased rate of fat 
metabolism, and a positive relationship between the two in our cachectic heart failure 
patients, we proposed that adiponectin may be a key mediator in the loss of adipose 
tissue and the development of cardiac cachexia.  
 
A positive association between adiponectin gene expression and lipolytic activity in 
the adipose tissue of healthy and obese women has previously been observed (Bullo 
et al, 2005).  Furthermore, adiponectin has been shown in animal and in vitro models 
to stimulate fatty acid uptake and oxidation in skeletal muscle. (Fruebis et al, 2001; 
Chen et al, 2005; Bruce et al, 2005). 
 
To develop our understanding of the relationship between adiponectin and fat 
metabolism we proceeded to investigate this further in a population of young healthy 
male subjects, using an exercise protocol specifically designed to maximise fat 
oxidation.  
 
Substrate energy metabolism during exercise is determined by the nature, intensity 
and duration of the activity being undertaken. During low-intensity exercise, at less 
than 50% peak oxygen consumption (peak VO2), fat is the predominant fuel, 
accounting for more than half of the total energy production. At 60￿65% peak VO2 
fat and carbohydrate contribute equally, and at higher intensity, 70-75% peak VO2, 
muscle glycogen is the major fuel (Romijn et al, 1993). Resistance exercise, through 
activation of growth hormone, is known to further promote fat oxidation (Bamman et  132
al, 2001; Nindl et al, 2001). Previous reports of the response of adiponectin to 
exercise in healthy subjects have been conflicting. Various programs of  exercise 
intensity and duration have been used, and while all have demonstrated significant 
increases in rates of fat metabolism most have reported no change in adiponectin 
concentration (Hulver et al, 2002; Yatagai et al, 2003; Ferguson et al, 2004; Jurimae 
et al, 2005; Ring-Dimitriou et al, 2006; Klimcakova et al, 2006; Brooks et al, 2006; 
Bobbert et al, 2007). 
 
We hypothesised that there may be a causal relationship between adiponectin 
concentration and rate of fat metabolism. To investigate this further we measured rate 
of fat oxidation and plasma adiponectin concentration in healthy male subjects during 
an exercise program, of resistance and prolonged, low intensity exercise, specifically 
designed to maximise fat metabolism.  133
Methods 
As part of an ongoing interest in our group in substrate energy metabolism during 
exercise, we designed an exercise protocol to maximise rate of fat metabolism. We 
proceeded to further investigate the relationship between adiponectin and rate of fat 
oxidation using this protocol in young healthy male subjects. 
 
Subjects 
We recruited eleven healthy male subjects with a mean age of 25 (4.2) years. The 
study was approved by the local ethics committee. Written informed consent was 
obtained from all participants. 
 
Body morphology 
All subjects had height, weight and body mass index measured. Skinfold thickness 
was measured with fat mass and fat free mass determined using the method described 
by Durnin and Womersley (Durnin et al, 1974). Harpenden callipers were used and 
skinfold thickness measured at four sites on the right hand side of the body (triceps, 
biceps, subscapular and suprailiac crest). 
 
Treadmill exercise testing 
Subjects attended on three separate occasions to perform a treadmill exercise test with 
respiratory gas analysis. 
 
At visit 1, peak oxygen consumption (peak VO2) was measured during uphill walking 
at a constant speed using a modification of the Taylor treadmill test (Taylor et al,  134
1955). Expired air samples were collected using Douglas bags, with oxygen 
consumption (VO2) and carbon dioxide (VCO2) production measured using a 
paramagnetic oxygen analyser (model 570A, Servomex, UK), an infrared carbon 
dioxide analyser (model 1400, Servomex, UK) and a dry gas analyser (Harvard 
Apparatus, UK). Heart rate was measured by short-range telemetry (Polar F1, 
Finland). The speed and gradient needed to elicit 50% peak VO2 for subsequent visits 
was determined on an individual basis from a nomogram predicting treadmill walking 
oxygen consumption (Workman et al, 1963). 
 
At visit 2 and 3 a baseline blood sample was obtained. Resting heart rate was 
recorded and 5 min expired gases were collected. Subjects were then asked to walk 
on a treadmill at an intensity of 50% peak VO2 for 90 min. At 30 min intervals heart 
rate was recorded, 2 min expired air samples were collected and a blood sample 
taken. At one visit subjects performed no resistance exercise before walking, and at 
the other visit the walking test was preceded by 20 min of high intensity resistance 
exercise. These second and third visits were carried out in random order. An 
additional blood sample was taken immediately on completing the resistance 
exercise. 
 
Resistance exercise 
Resistance exercise consisted of 2 sets of squats (each set with 20 repetitions 
followed by 30 pulses), 3 sets of press-ups (each set with 15 repetitions with the last 
repetition held for 20 seconds with the subjects face 1 inch off the floor), and 2 sets of  135
lunges on each leg (each set with 20 repetitions, followed by 30 lunge dips). This 
circuit was repeated until 20 minutes had elapsed. 
 
Rate of fat and carbohydrate oxidation 
Rates of fat and carbohydrate oxidation were calculated using the stoichiometric 
equations of Frayn as described previously in detail in chapter 4 (Frayn, 1983). 
 
Blood collection and analysis 
Blood samples were collected in cooled potassium EDTA tubes, placed on ice, and 
then centrifuged at 3000 rpm for 15 minutes at 4°C. The plasma was aliquoted and 
stored at ￿80 °C until analysis. Adiponectin was measured using a commercially 
available enzyme-linked immunosorbent assay kits (Quantikines, R&D systems). 
 
Statistical analysis 
Data are expressed as mean (± SEM). A repeated one-way analysis of variance 
(ANOVA) was used to compare differences between the measurements made at each 
time point during testing. Post-hoc analysis was performed with Student paired t-
tests. Statistical significance was taken at the 5% level.  136
Results 
Subject characteristics 
The subjects body morphology and peak oxygen consumption are detailed in table 
6.1. 
 
Mean height (m)  1.81 – 0.06 
Mean weight (kg)  89.3 – 8.3 
Mean BMI (kg.m
-2)  27.2 – 2.1 
Percentage body fat (%)  17.0 – 1.8 
Mean fat free mass (kg)  74.0 – 5.6 
Mean fat mass (kg)  15.3 – 3.0 
Mean peak VO2 (l.min
-1)  5.11 – 0.46 
 
Table 6.1 Body morphology and peak oxygen consumption. 
 
Expired gas analysis and substrate metabolism 
All subjects completed both 90-minute walking tests at 50% peak VO2 (table 6.2) 
(figure 6.1 and 6.2). There was no significant difference in VO2 at any time point 
between the walking test alone and the walking test preceded by resistance exercise. 
The rate of fat oxidation increased progressively during the 90-minute walking test (p 
< 0.01 for fat oxidation at rest vs 30 min, 30 min vs 60 min, and 60 min vs 90 min). 
Performing 20 minutes of resistance exercise prior to the 90 minute walking test 
significantly increased the rate of fat oxidation. The resting rate of fat oxidation was 
significantly higher after resistance exercise and remained higher than with walking 
alone at  each time point during the test (p < 0.01 for resistance and walking vs 
walking alone at rest, 30, 60 and 90 min).  137
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Figure 6.1. Expired gas analysis at rest and during exercise. ● Walking trial alone. 
○ Walking trial after resistance exercise. Differences between groups assessed by 
ANOVA. Post-hoc analysis with student￿s paired t-test. **p<0.01 for walking 
compared to resistance + walking. 
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Figure 6.2. Rate of fat and carbohydrate oxidation at rest and during exercise.  
● Walking trial alone. ○ Walking trial after resistance exercise. Differences between groups 
assessed by ANOVA. Post-hoc analysis with student￿s paired t-test. **p<0.01 for walking 
compared to resistance + walking. 
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 Walking  Resistance  + 
walking 
P value 
Resting VO2 (l.min
-1)  0.56 – 0.18  0.63 – 0.17  p>0.05 
Resting VCO2 (l.min
-1)  0.50 – 0.14  0.47 – 0.12  p<0.01 
Resting Fat Oxidation (g.min
-1)  0.11 – 0.02  0.28 – 0.02  p<0.01 
Resting CHO Oxidation (g.min
-1)  0.46 – 0.03  0.10 – 0.05  p<0.01 
      
30 min VO2 (l.min
-1)  2.58 – 0.74  2.58 – 0.61  p>0.05 
30 min VCO2 (l.min
-1)  2.37 – 0.64  2.10 – 0.37  p<0.01 
30 min Fat Oxidation (g.min
-1)  0.37 – 0.06  0.85 – 0.07  p<0.01 
30 min CHO Oxidation (g.min
-1)  2.45 – 0.15  1.17 – 0.13  p<0.01 
      
60 min VO2 (l.min
-1)  2.55 – 0.68  2.54 – 0.56  p>0.05 
60 min VCO2 (l.min
-1)  2.22 – 0.75  1.90 – 0.35  p<0.01 
60 min Fat Oxidation (g.min
-1)  0.58 – 0.06  1.12 – 0.05  p<0.01 
60 min CHO Oxidation (g.min
-1)  1.84 – 0.18  0.41 – 0.08  p<0.01 
      
90 min VO2 (l.min
-1)  2.60 – 0.50  2.63 – 0.52  p>0.05 
90 min VCO2 (l.min
-1)  2.04 – 0.54  1.94 – 0.32  p<0.01 
90 min Fat Oxidation (g.min
-1)  0.98 – 0.09  1.21 – 0.09  P<0.01 
90 min CHO Oxidation (g.min
-1)  0.85 – 0.21  0.29 – 0.18  P<0.01 
 
Table 6.2. Expired gas analysis and rate of fat and carbohydrate oxidation. 
Differences between groups assessed by ANOVA. Post-hoc analysis with student￿s paired t-
test.  140
Plasma adiponectin response to exercise 
Plasma adiponectin concentration increased during the walking test (figure 6.3). The 
difference became significant after 90 minutes of walking (Resting adiponectin 6.4 – 
0.7 µg/ml vs 90 min adiponectin 7.9 – 0.4 µg/ml, p < 0.01). 
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Figure 6.3. Increase in plasma adiponectin concentration during exercise.  ● 
Walking trial alone. ○ Walking trial after resistance exercise. Differences between groups 
assessed by ANOVA. Post-hoc analysis with student￿s paired t-test. **p<0.01 for walking 
compared to resistance + walking. 
 
 
Plasma adiponectin concentration increased earlier and to a higher level during the 
walking test preceded by resistance exercise. There was no significant difference in 
adiponectin concentrations immediately after resistance exercise or after 30 min of 
walking, but at 60 min the difference became significant (Resting adiponectin 6.1 – 
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0.5 µg/ml vs 60 min adiponectin 8.0 – 0.4 µg/ml, p < 0.01). The plasma adiponectin 
concentration at 60 and 90 min after resistance exercise were significantly higher than 
those at 60 and 90 min after walking alone (8.0 – 0.4 µg/ml vs 6.5 – 0.5 µg/ml at 60 
min; 9.4 – 0.5 µg/ml vs 7.9 – 0.4 µg/ml at 90 min, p < 0.01 for both comparisons). 
 
Relationship between adiponectin concentration and rate of fat oxidation 
Although both fat oxidation and adiponectin increased with walking, particularly after 
resistance exercise, no relationship was observed between the rate of fat oxidation 
and plasma adiponectin concentration (r = 0.15, p > 0.05 for walking alone; r = 0.11, 
p > 0.05 for walking and resistance exercise) (figure 6.4).  142
 
Figure 6.4. Relationship between plasma adiponectin concentration and rate of 
fat oxidation.  Adiponectin concentration (mcg.ml-1). Rate of fat oxidation (g.min-1). ● 
Walking trial alone. ○ Walking trial after resistance exercise. Relationship analysed using 
linear regression. 
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Discussion 
We found that our specifically designed exercise protocol of resistance exercise 
followed by prolonged, low intensity, aerobic exercise was successful in significantly 
increasing rates of fat metabolism. Plasma adiponectin increased during exercise, and 
more so during the protocol designed to maximise fat oxidation. Despite inducing 
both increased rates of fat oxidation and adiponectin concentrations, we found no 
association between them in these young healthy male subjects, in contrast to our 
observations in our cachectic heart failure patients. 
    
Our finding that plasma adiponectin concentration increased with exercise is contrary 
to most of the previous studies, which have reported little or no change (Hulver et al, 
2002; Yatagai et al, 2003; Ferguson et al, 2004; Jurimae et al, 2005; Klimcakova et 
al, 2006; Bobbert et al, 2007). Importantly, most of these studies used relatively 
short-term, high intensity exercise, which does not promote high levels of fat 
metabolism. Increased adiponectin has been previously demonstrated with prolonged 
strength training in diabetics and prolonged low to moderate intensity aerobic 
exercise in adults with a predisposition to the metabolic syndrome (Brook et al, 2006; 
Ring-Dimitriou et al, 2006). 
 
These observations suggest that increased plasma adiponectin concentration during 
exercise does not directly promote fat oxidation, and that adiponectin secretion is not 
directly related to the rate of fat oxidation in healthy subjects. It appears that the 
sympathetic nervous system and catecholamines are key mediators of lipolytic 
activity during exercise (McMurray et al, 2005). Prolonged, low intensity exercise  144
has been shown to increase circulating catecholamines, induce lipid mobilisation, and 
increase the rate of fat oxidation with time (Moro et al 2004). Rate of fat metabolism 
during exercise has also been observed to relate to the degree of growth hormone 
release (Pritzlaff et al, 2000). While plasma BNP is known to rise following 
endurance exercise, it has previously been reported to show no significant response to 
conventional exercise testing in healthy controls (Ohba et al, 2001; Nicholson et al, 
1993; Steele et al, 1997). In contrast, in patients with heart failure BNP appears to 
increase, from higher resting levels, during exercise testing (Maeder et al, 2007).  
 
It would have been interesting to have measured plasma BNP response to this specific 
exercise protocol, and to have looked at how this related to rates of fat oxidation and 
adiponectin concentration. Furthermore, a similar study conducted in our main study 
population would have been of interest, although with the degree of exercise 
limitation in the cachectic heart failure patients prolonged exercise would not have 
been possible. 
 
In conclusion, despite both rate of fat oxidation and plasma adiponectin concentration 
increasing significantly during exercise, we found no relationship between them. This 
suggests that adiponectin does not directly mediate fat oxidation, and its secretion is 
not directly related to the rate of fat oxidation in young healthy subjects during 
exercise.  145
 
 
 
 
CHAPTER 7 
 
GENERAL DISCUSSION  146
The prognostic importance of developing cachexia in heart failure was first 
highlighted ten years ago by Anker et al (Anker et al, 1997). More recent analyses 
from the large SOLVD (Studies of Left Ventricular Dysfunction) and CHARM 
(Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity) 
clinical trials have confirmed the strong relationship between weight loss or 
underweight status and impaired survival in heart failure (Anker et al, 2003; 
Kenchaiah et al, 2006; Kenchaiah et al, 2007). 
 
Although epidemiological data remain limited, cachexia appears to develop in a 
significant proportion of heart failure patients, from 8.5% at 6 months in the CHARM 
program to 42% at 35 months in the SOLVD trial (both using a definition of cachexia 
as ≥5% weight loss) (Kenchaiah et al, 2006; Anker et al, 2003). With the increasing 
prevalence of heart failure and improved longer-term survival with contemporary 
drug and device therapy, cachexia is anticipated to become an even more significant 
problem in the future. 
 
Muscle wasting has previously been assumed to be the major contributor to weight 
loss in heart failure, and has almost been considered to be synonymous with cachexia. 
The arbitrary, and easily clinically applied, definition of cachexia as a percentage loss 
of body weight over time has been widely employed in recent heart failure studies 
(Anker et al, 1997). The possible limitations of this definition and the importance of 
more detailed information regarding body composition was previously raised by a 
retrospective study by Lavie et al, who found that heart failure patients with clinical 
events, while having non-significantly lower BMI, had significantly lower percentage  147
body fat (Lavie et al, 2003). Furthermore, they found no difference in lean body mass 
on comparing event free survivors and those with clinical events, and a higher 
percentage body fat was the strongest independent predictor of event free survival. 
Interestingly, survival studies in chronic obstructive pulmonary disease (COPD) have 
shown a similar relationship between body mass and survival, with significantly 
higher mortality rates in underweight and normal-weight patients than in overweight 
and obese patients. More recent studies have shown that in COPD, in contrast to heart 
failure, fat-free mass is an independent predictor of mortality while fat mass is not 
(Schols AM et al, 2005). Therefore, contrary to previous suggestions, the nature of 
cachexia and how it develops appears to differ in these two chronic diseases. 
 
In our cachectic heart failure patients we found a significant reduction in fat mass but 
no significant loss of fat free mass. Some previous studies of cardiac cachexia have 
found loss of both fat mass and fat free mass. It is possible that the development of 
cachexia in heart failure could initially involve the loss of fat, followed by muscle and 
bone, and that our study population were in the early stages of this wasting process. 
Alternatively, the fact that previous studies have involved heterogeneous populations 
of heart failure patients while our study specifically involved only patients with 
coronary artery disease (CAD) raises the question of whether the development of 
cachexia and balance of tissue loss may differ in patients with heart failure of 
different aetiologies. 
 
In addition to finding no evidence of muscle wasting in our patients with cardiac 
cachexia, and despite increased concentrations of circulating cytokines, we found no  148
local activation of inflammatory cytokines or cell cycle regulators in skeletal muscle 
tissue. While our finding of increased circulating cytokines is consistent with 
previous studies, our muscle findings are contrary to the only other study quantifying 
cytokine expression in skeletal muscle in patients with heart failure (Levine et al 
1990, McMurray 1991, Anker et al 1999, Gielen et al 2003). Importantly, Geilin et 
al, who found  increased cytokine expression in muscle, studied a population of 
patients with predominantly idiopathic dilated cardiomyopathy (IDCM). Therefore a 
possible explanation for the discrepancy in our findings would be that, in contrast to 
patients with ischaemic heart disease, patients with IDCM have tissue as well as 
circulating cytokine activation.  
 
Circulating levels of TNF-α are known to be increased in COPD, and even more 
markedly in the presence of cachexia (Takabatake et al, 2000; DiFrancia et al, 1994). 
Indeed, circulating TNF-α concentrations in cachectic COPD patients appear 
markedly higher than in our cachectic heart failure patients (COPD-cachexia 70.2 
(100) pg/ml and HF-cachexia 27.2 (21.8-132.8) pg/ml) (DiFrancia et al, 1994). While 
this is an interesting observation we recognise the limitations of such a comparison. 
In the context of the conflicting findings of our study and Geilen et al, of even greater 
interest is a recent study measuring cytokines in the skeletal muscle of patients with 
￿weight stable￿ severe COPD using a human antibody array (Barreiro et al, 2007).  
Barreiro et al found significantly lower levels of TNF-α, and no difference in any of 
the other cytokines, in skeletal muscle of COPD patients compared to healthy 
controls, despite evidence of muscle weakness and oxidative stress.  
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Our finding of no muscle activation of cell cycle inhibitors is contrary to a previous 
study by our group reporting increased skeletal muscle expression of the cyclin 
dependent kinase (CDK) inhibitor p21 in COPD patients with cachexia. Importantly, 
the definition of cachexia widely used in COPD is more specific than in heart failure, 
requiring a reduction in fat-free mass in addition to body mass index (American 
Thoracic Society/European Respiratory Society, 1999). Thus, having found no 
significant loss of muscle mass in our cachectic heart failure patients the absence of 
activation of cell cycle inhibitors in the muscle is not surprising.  
 
In addition to finding that the weight loss in our cachectic heart failure patients was 
predominantly due to loss of fat mass, we also found that they had altered energy 
metabolism, with higher rates of fat metabolism compared to heart failure patients 
without cachexia. This raised the question of what might be mediating this increased 
fat metabolism? While the literature supports a significant contribution of the 
sympathetic nervous system and catecholamines, it is clear that there are other 
important mediators involved: Both increased circulating TNF-α and adipose tissue 
derived TNF-α have been suggested to mediate depletion of adipose tissue mass in 
cachexia (Levine et al, 1990; McMurray et al, 1991; Dutka et al, 1993; Anker et al, 
1997; Argiles et al, 1997; Kern et al, 1995; Warne et al, 2003); the adipose tissue 
specific hormone adiponectin is known to have an inverse relationship to body fat and 
induces weight loss in experimental animal models (Maeda et al, 1996; Chandran et 
al, 2003; Meier et al, 2004; Yamauchi et al, 2002; Bruun et al, 2003; Wang et al, 
2006; Degawa-Yamauchi et al, 2005; Carey et al, 2006; Fruebis et al, 2001; Masaki 
et al, 2003); and the natriuretic peptides, well established as predictors of outcome  150
and markers of heart failure severity, appear to have additional lipolytic and lipid-
mobilising actions (Sengenes et al, 2000).  
 
We found that our cachectic heart failure patients, in addition to reduced body fat and 
increased fat metabolism, had markedly elevated serum adiponectin concentrations, 
and non-significantly elevated plasma BNP levels, compared to heart failure patients 
without cachexia. There was a positive association between adiponectin and BNP. 
Both negatively correlated with BMI and percentage body fat, and positively 
correlated with serum TNF-α concentration. There was a positive association between 
rate of fat oxidation and adiponectin concentration, but no relationship with BNP.  
 
At the very least, our findings suggest preservation of the supposed physiological, 
inverse, relationship between adiponectin and fat mass in cachexia, and illustrate the 
role of BNP as a marker of disease severity (Chandran et al, 2003; Meier et al, 2004).   
While the relationship with TNF-α could be explained by the proposed anti-
inflammatory role of adiponectin, TNF-α has been suggested to increase adiponectin 
secretion (Bruun et al, 2003; Wang et al, 2006; Degawa-Yamauchi et al, 2005; Carey 
et al, 2006). More interestingly, our findings raise the possibility that adiponectin, 
possibly under the influence of TNF-α and BNP, contributes to increased fat 
metabolism,  loss of fat mass and the development of cachexia in heart failure. 
Alternatively, BNP could be the key mediator of increased lipolysis and loss of body 
fat, and in doing so promotes adiponectin secretion. A direct way of establishing the 
￿cause and effect￿ relationship between increased adiponectin and BNP and reduced  151
body weight would be to examine change in weight, body fat and rate of fat 
metabolism following the administration of each peptide. 
 
To determine whether there might be a causal relationship beween adiponectin and 
rate of fat metabolism we conducted an additional study in young healthy male 
subjects. This exercise study, designed specifically to maximise fat metabolism, 
found no direct relationship between adiponectin and the rate of fat oxidation. From 
this we concluded that adiponectin does not directly promote fat oxidation, and its 
secretion is not directly related to the rate of fat oxidation, in young healthy subjects 
during exercise. While this might suggest that the relationship we observed in our 
heart failure patients could be mediated by another factor, it is important to 
distinguish between a rapid, short-term change in substrate utilisation during exercise 
in healthy subjects and the chronic abnormal energy metabolism of heart failure. 
 
There are a number of limitations in the investigations that contribute to this thesis. 
Due to the technical requirements of the project, and the not inconsiderable demands 
on the volunteers, the subject numbers are relatively small. In addition, patients with 
heart failure and cachexia are often so sick as to preclude inclusion in a study like 
this, introducing a selective bias towards patients with less severe disease. Subjects 
did not undergo a familiarisation treadmill test, which is known to produce more 
reliable exercise data. The IDCM subject group were recruited as an amendment to 
the original protocol and consequently had limited characterisation. It would have 
been interesting in light the conflicting findings with Geilen et al to perform skeletal 
muscle analysis in our IDCM group. Furthermore, it would have been interesting to  152
look at cytokine activation in the adipose tissue, but at the time the study was 
designed muscle wasting was considered to be the major manifestation of cardiac 
cachexia. Our assessment of energy metabolism would have been enhanced if we had 
also measured free fatty acids and urinary nitrogen. There were a number of 
methodological limitations discussed previously in the general methods section and 
results chapters. Finally, it is possible that the lack of significant difference observed 
between some of the biochemical parameters we measured might be the result of a 
type II error. 
 
This work has raised a number of questions requiring further study. Are cachectic 
heart failure patients just those patients with the most advanced heart failure? Our 
cachectic population had all the markers of advanced heart failure with the lowest 
LVEF and peak VO2, and the worst NYHA classification, but we know that there are 
patients with advanced heart failure who do not have cachexia. It would be interesting 
to compare heart failure patients matched for the established markers of disease 
severity with and without cachexia. Do cachectic heart failure patients initially lose 
body fat with subsequent muscle wasting? Is the change in body composition the 
same in patients with heart failure of different aetiologies? Both these questions could 
be addressed by prospectively monitoring changes in body composition in a 
population of heart failure patients. Are adiponectin and BNP mediators of the loss of 
adipose tissue? As suggested earlier this could be determined by a study examining 
change in weight, body fat and rate of fat metabolism following the administration of 
each peptide. 
  153
In conclusion, cachexia in patients with heart failure and stable coronary artery 
disease predominantly involves the loss of body fat, with no evidence of muscle 
wasting or inflammation. This is associated with elevated circulating levels of TNF-α, 
adiponectin and BNP, with the observed relationships between these peptides, and of 
each with body composition, suggesting that while this may be bystander 
phenomenology each may play an integral role in the altered energy metabolism, loss 
of body fat, and development of cachexia in heart failure.  154
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